1
|
Qousain Naqvi ST, Muhammad SA, Guo J, Zafar S, Ali A, Anderson LJ, Rostad CA, Bai B. Experimental trials of predicted CD4 + and CD8 + T-cell epitopes of respiratory syncytial virus. Front Immunol 2024; 15:1349749. [PMID: 38629077 PMCID: PMC11018974 DOI: 10.3389/fimmu.2024.1349749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 03/11/2024] [Indexed: 04/19/2024] Open
Abstract
Background Respiratory syncytial virus (RSV) is the most common cause of viral lower respiratory tract infections (LRTIs) in young children around the world and an important cause of LRTI in the elderly. The available treatments and FDA-approved vaccines for RSV only lessen the severity of the infection and are recommended for infants and elderly people. Methods We focused on developing a broad-spectrum vaccine that activates the immune system to directly combat RSV. The objective of this study is to identify CD4+ and CD8+ T-cell epitopes using an immunoinformatics approach to develop RSV vaccines. The efficacy of these peptides was validated through in-vitro and in-vivo studies involving healthy and diseased animal models. Results For each major histocompatibility complex (MHC) class-I and II, we found three epitopes of RSV proteins including F, G, and SH with an antigenic score of >0.5 and a projected SVM score of <5. Experimental validation of these peptides on female BALB/c mice was conducted before and after infection with the RSV A2 line 19f. We found that the 3RVMHCI (CD8+) epitope of the F protein showed significant results of white blood cells (19.72 × 103 cells/μl), neutrophils (6.01 × 103 cells/μl), lymphocytes (12.98 × 103 cells/μl), IgG antibodies (36.9 µg/ml), IFN-γ (86.96 ng/L), and granzyme B (691.35 pg/ml) compared to control at the second booster dose of 10 µg. Similarly, 4RVMHCII (CD4+) of the F protein substantially induced white blood cells (27.08 × 103 cells/μl), neutrophils (6.58 × 103 cells/μl), lymphocytes (16.64 × 103 cells/μl), IgG antibodies (46.13 µg/ml), IFN-γ (96.45 ng/L), and granzyme B (675.09 pg/ml). In-vitro studies showed that 4RVMHCII produced a significant level of antibodies in sera on day 45 comparable to mice infected with the virus. 4RVMHCII also induced high IFN-γ and IL-2 secretions on the fourth day of the challenge compared to the preinfectional stage. Conclusion In conclusion, epitopes of the F protein showed considerable immune response and are suitable for further validation.
Collapse
Affiliation(s)
| | - Syed Aun Muhammad
- Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan
| | - Jinlei Guo
- School of Intelligent Medical Engineering, Sanquan College of Xinxiang Medical University, Xinxiang, Henan, China
| | - Sidra Zafar
- Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan
| | - Amjad Ali
- Atta-ur-Rehman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan
| | - Larry J. Anderson
- Department of Pediatrics and Children’s Healthcare of Atlanta, Emory University, Atlanta, GA, United States
| | - Christina A. Rostad
- Department of Pediatrics and Children’s Healthcare of Atlanta, Emory University, Atlanta, GA, United States
| | - Baogang Bai
- School of Information and Technology, Wenzhou Business College, Wenzhou, Zhejiang, China
- Engineering Research Center of Intelligent Medicine, Wenzhou, Zhejiang Province, China
- The First School of Medical, School of Information and Engineering, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| |
Collapse
|
2
|
Anderson LJ, Jadhao SJ, Hussaini L, Ha B, McCracken CE, Gibson T, Yildirim I, Yi J, Stephens K, Korski C, Kao C, Sun H, Lee CY, Jaunarajs A, Rostad CA, Anderson EJ. Development and comparison of immunologic assays to detect primary RSV infections in infants. Front Immunol 2024; 14:1332772. [PMID: 38283339 PMCID: PMC10811012 DOI: 10.3389/fimmu.2023.1332772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 12/18/2023] [Indexed: 01/30/2024] Open
Abstract
Effective respiratory syncytial virus (RSV) vaccines have been developed and licensed for elderly adults and pregnant women but not yet for infants and young children. The RSV immune state of the young child, i.e., previously RSV infected or not, is important to the conduct and interpretation of epidemiology studies and vaccine clinical trials. To address the need for sensitive assays to detect immunologic evidence of past infection, we developed, characterized, and evaluated 7 assays including 4 IgG antibody enzyme immunoassays (EIAs), two neutralizing antibody assays, and an IFN-γ EliSpot (EliSpot) assay. The four IgG EIAs used a subgroup A plus subgroup B RSV-infected Hep-2 cell lysate antigen (Lysate), an expressed RSV F protein antigen (F), an expressed subgroup A G protein antigen (Ga), or an expressed subgroup B G protein (Gb) antigen. The two neutralizing antibody assays used either a subgroup A or a subgroup B RSV strain. The EliSpot assay used a sucrose cushion purified combination of subgroup A and subgroup B infected cell lysate. All seven assays had acceptable repeatability, signal against control antigen, lower limit of detection, and, for the antibody assays, effect of red cell lysis, lipemia and anticoagulation of sample on results. In 44 sera collected from children >6 months after an RSV positive illness, the lysate, F, Ga and Gb IgG EIAs, and the subgroup A and B neutralizing antibody assays, and the EliSpot assays were positive in 100%, 100%, 86%, 95%, 43%, and 57%, respectively. The Lysate and F EIAs were most sensitive for detecting RSV antibody in young children with a documented RSV infection. Unexpectedly, the EliSpot assay was positive in 9/15 (60%) of PBMC specimens from infants not exposed to an RSV season, possibly from maternal microchimerism. The Lysate and F EIAs provide good options to reliably detect RSV antibodies in young children for epidemiologic studies and vaccine trials.
Collapse
Affiliation(s)
- Larry J Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Samadhan J Jadhao
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Laila Hussaini
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Binh Ha
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Courtney E McCracken
- Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Theda Gibson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Inci Yildirim
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Jumi Yi
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Kathy Stephens
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Chelsea Korski
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Carol Kao
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Heying Sun
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Chun Yi Lee
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | | | - Christina A Rostad
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Evan J Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States
| |
Collapse
|
3
|
Rosas-Salazar C, Chirkova T, Gebretsadik T, Chappell JD, Peebles RS, Dupont WD, Jadhao SJ, Gergen PJ, Anderson LJ, Hartert TV. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet 2023; 401:1669-1680. [PMID: 37086744 PMCID: PMC10367596 DOI: 10.1016/s0140-6736(23)00811-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 01/19/2023] [Accepted: 01/31/2023] [Indexed: 04/24/2023]
Abstract
BACKGROUND Early-life severe respiratory syncytial virus (RSV) infection has been associated with the onset of childhood wheezing illnesses. However, the relationship between RSV infection during infancy and the development of childhood asthma is unclear. We aimed to assess the association between RSV infection during infancy and childhood asthma. METHODS INSPIRE is a large, population-based, birth cohort of healthy infants with non-low birthweight born at term between June and December, 2012, or between June and December, 2013. Infants were recruited from 11 paediatric practices across middle Tennessee, USA. We ascertained RSV infection status (no infection vs infection) in the first year of life using a combination of passive and active surveillance with viral identification through molecular and serological techniques. Children were then followed up prospectively for the primary outcome of 5-year current asthma, which we analysed in all participants who completed 5-year follow-up. Statistical models, which were done for children with available data, were adjusted for child's sex, race and ethnicity, any breastfeeding, day-care attendance during infancy, exposure to second-hand smoke in utero or during early infancy, and maternal asthma. FINDINGS Of 1946 eligible children who were enrolled in the study, 1741 (89%) had available data to assess RSV infection status in the first year of life. The proportion of children with RSV infection during infancy was 944 (54%; 95% CI 52-57) of 1741 children. The proportion of children with 5-year current asthma was lower among those without RSV infection during infancy (91 [16%] of 587) than those with RSV infection during infancy (139 [21%] of 670; p=0·016). Not being infected with RSV during infancy was associated with a 26% lower risk of 5-year current asthma than being infected with RSV during infancy (adjusted RR 0·74, 95% CI 0·58-0·94, p=0·014). The estimated proportion of 5-year current asthma cases that could be prevented by avoiding RSV infection during infancy was 15% (95% CI 2·2-26·8). INTERPRETATION Among healthy children born at term, not being infected with RSV in the first year of life was associated with a substantially reduced risk of developing childhood asthma. Our findings show an age-dependent association between RSV infection during infancy and childhood asthma. However, to definitively establish causality, the effect of interventions that prevent, delay, or decrease the severity of the initial RSV infection on childhood asthma will need to be studied. FUNDING US National Institutes of Health.
Collapse
Affiliation(s)
| | - Tatiana Chirkova
- Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Tebeb Gebretsadik
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - James D Chappell
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - R Stokes Peebles
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - William D Dupont
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Samadhan J Jadhao
- Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Peter J Gergen
- Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, Bethesda, MA, USA
| | - Larry J Anderson
- Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Tina V Hartert
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
| |
Collapse
|
4
|
Bergeron HC, Murray J, Arora A, Nuñez Castrejon AM, DuBois RM, Anderson LJ, Kauvar LM, Tripp RA. Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein. Viruses 2023; 15:1067. [PMID: 37243153 PMCID: PMC10221658 DOI: 10.3390/v15051067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 04/21/2023] [Accepted: 04/26/2023] [Indexed: 05/28/2023] Open
Abstract
The respiratory syncytial virus (RSV) causes significant respiratory disease in young infants and the elderly. Immune prophylaxis in infants is currently limited to palivizumab, an anti-RSV fusion (F) protein monoclonal antibody (mAb). While anti-F protein mAbs neutralize RSV, they are unable to prevent aberrant pathogenic responses provoked by the RSV attachment (G) protein. Recently, the co-crystal structures of two high-affinity anti-G protein mAbs that bind the central conserved domain (CCD) at distinct non-overlapping epitopes were solved. mAbs 3D3 and 2D10 are broadly neutralizing and block G protein CX3C-mediated chemotaxis by binding antigenic sites γ1 and γ2, respectively, which is known to reduce RSV disease. Previous studies have established 3D3 as a potential immunoprophylactic and therapeutic; however, there has been no similar evaluation of 2D10 available. Here, we sought to determine the differences in neutralization and immunity to RSV Line19F infection which recapitulates human RSV infection in mouse models making it useful for therapeutic antibody studies. Prophylactic (24 h prior to infection) or therapeutic (72 h post-infection) treatment of mice with 3D3, 2D10, or palivizumab were compared to isotype control antibody treatment. The results show that 2D10 can neutralize RSV Line19F both prophylactically and therapeutically, and can reduce disease-causing immune responses in a prophylactic but not therapeutic context. In contrast, 3D3 was able to significantly (p < 0.05) reduce lung virus titers and IL-13 in a prophylactic and therapeutic regimen suggesting subtle but important differences in immune responses to RSV infection with mAbs that bind distinct epitopes.
Collapse
Affiliation(s)
- Harrison C. Bergeron
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
| | - Jackelyn Murray
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
| | - Aakash Arora
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
| | - Ana M. Nuñez Castrejon
- Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA; (A.M.N.C.)
| | - Rebecca M. DuBois
- Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA; (A.M.N.C.)
| | - Larry J. Anderson
- Division of Pediatric Infectious Disease, Emory University School of Medicine, Atlanta, GA 30322, USA;
| | | | - Ralph A. Tripp
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
| |
Collapse
|
5
|
Chen X, Ciric C, Gibson T, Anderson LJ, Anderson EJ, Rostad CA. Longitudinal Neutralizing and Functional Antibody Responses to SARS-CoV-2 Variants following mRNA COVID-19 Vaccination. Open Forum Infect Dis 2023; 10:ofad167. [PMID: 37065985 PMCID: PMC10096895 DOI: 10.1093/ofid/ofad167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 03/24/2023] [Indexed: 03/30/2023] Open
Abstract
Abstract
In this longitudinal prospective cohort of healthy U.S. adults, we found that COVID-19 mRNA primary series and booster vaccinations elicited high titers of broadly cross-reactive neutralizing and ADCC antibodies, which gradually waned over 6 months and particularly against SARS-CoV-2 variants. This data supports the indication for a subsequent booster vaccination.
Collapse
Affiliation(s)
- Xuemin Chen
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Caroline Ciric
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Theda Gibson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Larry J Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Evan J Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Christina A Rostad
- Correspondence: Christina A. Rostad, MD, Department of Pediatrics, Emory University School of Medicine, 2015 Uppergate Dr NE, Atlanta, GA 30322 ()
| |
Collapse
|
6
|
Lawless D, McKennan CG, Das SR, Junier T, Xu ZM, Anderson LJ, Gebretsadik T, Shilts MH, Larkin E, Rosas-Salazar C, Chappell JD, Fellay J, Hartert TV. Viral genetic determinants of prolonged respiratory syncytial virus infection among infants in a healthy term birth cohort. J Infect Dis 2022; 227:1194-1202. [PMID: 36375000 PMCID: PMC10175068 DOI: 10.1093/infdis/jiac442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 11/01/2022] [Accepted: 11/05/2022] [Indexed: 11/16/2022] Open
Abstract
Abstract
Background
Respiratory syncytial virus (RSV) is associated with acute respiratory infection. We sought to identify RSV variants associated with prolonged infection.
Methods
Among healthy term infants we identified those with prolonged RSV infection and conducted 1) a human GWAS to test the dependence of infection risk on host genotype, 2) a viral GWAS for association with prolonged RSV infection using RSV whole-genome sequencing, 3) an analysis of all viral public sequences, 4) an assessment of immunological responses, and 5) a summary of all major functional data. Analyses were adjusted for viral/human population structure and host factors associated with infection risk.
Results
We identified p.E123K/D and p.P218T/S/L in G protein that were associated with prolonged infection (Padj = 0.01). We found no evidence of host genetic risk for infection. The RSV variant positions approximate sequences that could bind a putative viral receptor, heparan sulfate.
Conclusions
Using analysis of both viral and host genetics we identified a novel RSV variant associated with prolonged infection in healthy infants and no evidence supporting host genetic susceptibility to infection. As the capacity of RSV for chronicity and its viral reservoir are not defined, these findings are important for understanding the impact of RSV on chronic disease and endemicity.
Collapse
Affiliation(s)
- Dylan Lawless
- Global Health Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne , Lausanne , Switzerland
| | - Christopher G McKennan
- Department of Statistics, University of Pittsburgh, Pittsburgh, Pennsylvania , United States of America
| | - Suman R Das
- Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , United States of America
| | - Thomas Junier
- Swiss Institute of Bioinformatics, Vital-IT Group , Switzerland
| | - Zhi Ming Xu
- Global Health Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne , Lausanne , Switzerland
| | - Larry J Anderson
- Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta , Atlanta, Georgia , United States of America
| | - Tebeb Gebretsadik
- Department of Biostatistics, Vanderbilt University Medical Center , Nashville, Tennessee , United States of America
| | - Meghan H Shilts
- Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , United States of America
| | - Emma Larkin
- Division of Allergy, Immunology, and Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , United States of America
| | - Christian Rosas-Salazar
- Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee , United States of America
| | - James D Chappell
- Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee , United States of America
| | - Jacques Fellay
- Global Health Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne , Lausanne , Switzerland
- Biomedical Data Science Center, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland
| | - Tina V Hartert
- Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , United States of America
- Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee , United States of America
| |
Collapse
|
7
|
Roe MK, Perez MA, Hsiao HM, Lapp SA, Sun HY, Jadhao S, Young AR, Batista YS, Reed RC, Taz A, Piantadosi A, Chen X, Liang B, Koval M, Snider TA, Moore ML, Anderson EJ, Anderson LJ, Stobart CC, Rostad CA. An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice. J Infect Dis 2022; 227:50-60. [PMID: 36281651 PMCID: PMC9796166 DOI: 10.1093/infdis/jiac382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Revised: 09/09/2022] [Accepted: 10/31/2022] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Respiratory syncytial virus (RSV) is a leading viral respiratory pathogen in infants. The objective of this study was to generate RSV live-attenuated vaccine (LAV) candidates by removing the G-protein mucin domains to attenuate viral replication while retaining immunogenicity through deshielding of surface epitopes. METHODS Two LAV candidates were generated from recombinant RSV A2-line19F by deletion of the G-protein mucin domains (A2-line19F-G155) or deletion of the G-protein mucin and transmembrane domains (A2-line19F-G155S). Vaccine attenuation was measured in BALB/c mouse lungs by fluorescent focus unit (FFU) assays and real-time polymerase chain reaction (RT-PCR). Immunogenicity was determined by measuring serum binding and neutralizing antibodies in mice following prime/boost on days 28 and 59. Efficacy was determined by measuring RSV lung viral loads on day 4 postchallenge. RESULTS Both LAVs were undetectable in mouse lungs by FFU assay and elicited similar neutralizing antibody titers compared to A2-line19F on days 28 and 59. Following RSV challenge, vaccinated mice showed no detectable RSV in the lungs by FFU assay and a significant reduction in RSV RNA in the lungs by RT-PCR of 560-fold for A2-line19F-G155 and 604-fold for A2-line19F-G155S compared to RSV-challenged, unvaccinated mice. CONCLUSIONS Removal of the G-protein mucin domains produced RSV LAV candidates that were highly attenuated with retained immunogenicity.
Collapse
Affiliation(s)
- Molly K Roe
- Department of Biological Sciences, Butler University, Indianapolis, Indiana, USA
| | - Maria A Perez
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA
| | - Hui-Mien Hsiao
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA
| | - Stacey A Lapp
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA
| | - He-Ying Sun
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA
| | - Samadhan Jadhao
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA
| | - Audrey R Young
- Department of Biological Sciences, Butler University, Indianapolis, Indiana, USA
| | - Yara S Batista
- Department of Biological Sciences, Butler University, Indianapolis, Indiana, USA
| | - Ryan C Reed
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Azmain Taz
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Anne Piantadosi
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Xuemin Chen
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA
| | - Bo Liang
- Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Michael Koval
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Timothy A Snider
- Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, Oklahoma, USA
| | | | - Evan J Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA,Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Larry J Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA
| | | | - Christina A Rostad
- Correspondence: Christina A. Rostad, MD, Emory Children's Center, 2015 Uppergate Drive NE, Atlanta, GA 30322 ()
| |
Collapse
|
8
|
Rosas-Salazar C, Shilts MH, Tang ZZ, Hong Q, Turi KN, Snyder BM, Wiggins DA, Lynch CE, Gebretsadik T, Peebles RS, Anderson LJ, Das SR, Hartert TV. Exclusive breast-feeding, the early-life microbiome and immune response, and common childhood respiratory illnesses. J Allergy Clin Immunol 2022; 150:612-621. [PMID: 35283139 PMCID: PMC9463089 DOI: 10.1016/j.jaci.2022.02.023] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Revised: 02/11/2022] [Accepted: 02/14/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND The impact of breast-feeding on certain childhood respiratory illnesses remains controversial. OBJECTIVE We sought to examine the effect of exclusive breast-feeding on the early-life upper respiratory tract (URT) and gut microbiome, the URT immune response in infancy, and the risk of common pediatric respiratory diseases. METHODS We analyzed data from a birth cohort of healthy infants with prospective ascertainment of breast-feeding patterns and common pediatric pulmonary and atopic outcomes. In a subset of infants, we also characterized the URT and gut microbiome using 16S ribosomal RNA sequencing and measured 9 URT cytokines using magnetic bead-based assays. RESULTS Of the 1949 infants enrolled, 1495 (76.71%) had 4-year data. In adjusted analyses, exclusive breast-feeding (1) had an inverse dose-response on the ⍺-diversity of the early-life URT and gut microbiome, (2) was positively associated with the URT levels of IFN-α, IFN-γ, and IL-17A in infancy, and (3) had a protective dose-response on the development of a lower respiratory tract infection in infancy, 4-year current asthma, and 4-year ever allergic rhinitis (odds ratio [95% CI] for each 4 weeks of exclusive breast-feeding, 0.95 [0.91-0.99], 0.95 [0.90-0.99], and 0.95 [0.92-0.99], respectively). In exploratory analyses, we also found that the protective association of exclusive breast-feeding on 4-year current asthma was mediated through its impact on the gut microbiome (P = .03). CONCLUSIONS Our results support a protective causal role of exclusive breast-feeding in the risk of developing a lower respiratory tract infection in infancy and asthma and allergic rhinitis in childhood. They also shed light on potential mechanisms of these associations, including the effect of exclusive breast-feeding on the gut microbiome.
Collapse
Affiliation(s)
| | - Meghan H Shilts
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
| | - Zheng-Zheng Tang
- Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wis
| | - Qilin Hong
- Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wis
| | - Kedir N Turi
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
| | - Brittney M Snyder
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
| | - Derek A Wiggins
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
| | - Christian E Lynch
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
| | - Tebeb Gebretsadik
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tenn
| | - R Stokes Peebles
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
| | - Larry J Anderson
- Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, Ga
| | - Suman R Das
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tenn.
| | - Tina V Hartert
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
| |
Collapse
|
9
|
Rostad CA, Chen X, Sun HY, Hussaini L, Lu A, Perez MA, Hsiao HM, Anderson LJ, Anderson EJ. Functional antibody responses to SARS-CoV-2 variants in children with COVID-19, MIS-C, and after two doses of BNT162b2 vaccination. J Infect Dis 2022; 226:1237-1242. [PMID: 35639597 PMCID: PMC9213873 DOI: 10.1093/infdis/jiac215] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 05/24/2022] [Indexed: 11/12/2022] Open
Abstract
Background Although neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) correlate with protection against coronavirus disease 2019 (COVID-19), little is known about the neutralizing and antibody-dependent cell-mediated cytotoxicity (ADCC) responses to COVID-19, multisystem inflammatory syndrome in children (MIS-C), and COVID-19 vaccination in children. Methods We enrolled children 0–21 years of age with a history of COVID-19 (n = 13), MIS-C (n = 13), or 2 doses of BNT162b2 vaccination (n = 14) into a phlebotomy protocol. We measured pseudovirus neutralizing and functional ADCC antibodies to SARS-CoV-2 variants, including Omicron (B.1.1.529). Results The primary BNT162b2 vaccination series elicited higher neutralizing and ADCC responses with greater breadth to SARS-CoV-2 variants than COVID-19 or MIS-C, although these were diminished against Omicron. Conclusions Serologic responses were significantly reduced against variants, particularly Omicron.
Collapse
Affiliation(s)
- Christina A Rostad
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Xuemin Chen
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - He-Ying Sun
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Laila Hussaini
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Austin Lu
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Maria A Perez
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Hui-Mien Hsiao
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Larry J Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Evan J Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.,Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States.,Department of Infectious Diseases, University of Georgia, Athens, GA, United States
| |
Collapse
|
10
|
Chirkova T, Rosas-Salazar C, Gebretsadik T, Jadhao SJ, Chappell JD, Peebles RS, Dupont WD, Newcomb DC, Berdnikovs S, Gergen PJ, Hartert TV, Anderson LJ. Effect of Infant RSV Infection on Memory T Cell Responses at Age 2-3 Years. Front Immunol 2022; 13:826666. [PMID: 35371035 PMCID: PMC8967987 DOI: 10.3389/fimmu.2022.826666] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 02/23/2022] [Indexed: 11/13/2022] Open
Abstract
Background It is unknown whether RSV infection in infancy alters subsequent RSV immune responses. Methods In a nested cohort of healthy, term children, peripheral blood mononuclear cells (PBMCs) were collected at ages 2-3 years to examine RSV memory T cell responses among children previously RSV infected during infancy (first year of life) compared to those RSV-uninfected during infancy. The presence vs. absence of infant RSV infection was determined through a combination of RSV molecular and serologic testing. Memory responses were measured in RSV stimulated PBMCs. Results Compared to children not infected with RSV during the first year of life, children infected with RSV during infancy had lower memory T cell responses at ages 2-3 years to in vitro stimulation with RSV for most tested type-1 and type-17 markers for a number of memory T cell subsets. Conclusions RSV infection in infancy has long-term effects on memory T cell responses. This is the first study to show the potential for RSV infection in infancy to have long-term effects on the immune memory irrespective of the severity of the infection. Our results suggest a possible mechanism through which infant RSV infection may result in greater risk of subsequent childhood respiratory viral morbidity, findings also relevant to vaccine development.
Collapse
Affiliation(s)
- Tatiana Chirkova
- Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, United States
| | - Christian Rosas-Salazar
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Tebeb Gebretsadik
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Samadhan J. Jadhao
- Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, United States
| | - James D. Chappell
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States
| | - R. Stokes Peebles
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - William D. Dupont
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Dawn C. Newcomb
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Sergejs Berdnikovs
- Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
| | - Peter J. Gergen
- Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, United States
| | - Tina V. Hartert
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Larry J. Anderson
- Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, United States
| |
Collapse
|
11
|
Rosas-Salazar C, Tang ZZ, Shilts MH, Turi KN, Hong Q, Wiggins DA, Lynch CE, Gebretsadik T, Chappell JD, Peebles RS, Anderson LJ, Das SR, Hartert TV. Upper respiratory tract bacterial-immune interactions during respiratory syncytial virus infection in infancy. J Allergy Clin Immunol 2022; 149:966-976. [PMID: 34534566 PMCID: PMC9036861 DOI: 10.1016/j.jaci.2021.08.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 07/23/2021] [Accepted: 08/26/2021] [Indexed: 01/04/2023]
Abstract
BACKGROUND The risk factors determining short- and long-term morbidity following acute respiratory infection (ARI) due to respiratory syncytial virus (RSV) in infancy remain poorly understood. OBJECTIVES Our aim was to examine the associations of the upper respiratory tract (URT) microbiome during RSV ARI in infancy with the acute local immune response and short- and long-term clinical outcomes. METHODS We characterized the URT microbiome by 16S ribosomal RNA sequencing and assessed the acute local immune response by measuring 53 immune mediators with high-throughput immunoassays in 357 RSV-infected infants. Our short- and long-term clinical outcomes included several markers of disease severity and the number of wheezing episodes in the fourth year of life, respectively. RESULTS We found several specific URT bacterial-immune mediator associations. In addition, the Shannon ⍺-diversity index of the URT microbiome was associated with a higher respiratory severity score (β =.50 [95% CI = 0.13-0.86]), greater odds of a lower ARI (odds ratio = 1.63 [95% CI = 1.10-2.43]), and higher number of wheezing episodes in the fourth year of life (β = 0.89 [95% CI = 0.37-1.40]). The Jaccard β-diversity index of the URT microbiome differed by level of care required (P = .04). Furthermore, we found an interaction between the Shannon ⍺-diversity index of the URT microbiome and the first principal component of the acute local immune response on the respiratory severity score (P = .048). CONCLUSIONS The URT microbiome during RSV ARI in infancy is associated with the acute local immune response, disease severity, and number of wheezing episodes in the fourth year of life. Our results also suggest complex URT bacterial-immune interactions that can affect the severity of the RSV ARI.
Collapse
Affiliation(s)
- Christian Rosas-Salazar
- Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN
| | - Zheng-Zheng Tang
- Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI
| | - Meghan H. Shilts
- Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Kedir N. Turi
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Qilin Hong
- Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI
| | - Derek A Wiggins
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Christian E. Lynch
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Tebeb Gebretsadik
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
| | - James D. Chappell
- Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN
| | - R. Stokes Peebles
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Larry J. Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University and Children’s Healthcare of Atlanta, Atlanta, GA
| | - Suman R. Das
- Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN,Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN,Corresponding Authors: Suman R. Das, PhD, Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South, Medical Center North, Suite A2200, Nashville, TN 37232, Phone: (615) 322-0322, Fax: (615) 343-6160, ; Tina V. Hartert, MD, MPH, Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 450, Nashville, TN 37232, Phone: (615) 936-3597, Fax: (615) 936-1269,
| | - Tina V. Hartert
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN,Corresponding Authors: Suman R. Das, PhD, Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South, Medical Center North, Suite A2200, Nashville, TN 37232, Phone: (615) 322-0322, Fax: (615) 343-6160, ; Tina V. Hartert, MD, MPH, Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 450, Nashville, TN 37232, Phone: (615) 936-3597, Fax: (615) 936-1269,
| |
Collapse
|
12
|
Affiliation(s)
- Larry J Anderson
- From the Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta (L.J.A.); and the Department of Medicine, University of Rochester School of Medicine, Rochester, NY (E.E.W.)
| | - Edward E Walsh
- From the Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta (L.J.A.); and the Department of Medicine, University of Rochester School of Medicine, Rochester, NY (E.E.W.)
| |
Collapse
|
13
|
Chen X, Sun HY, Lee CY, Rostad CA, Trost J, Abreu RB, Carlock MA, Wilson JR, Gansebom S, Ross TM, Steinhauer DA, Anderson EJ, Anderson LJ. Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination. Virology 2022; 569:44-55. [PMID: 35255298 PMCID: PMC9013517 DOI: 10.1016/j.virol.2022.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 02/18/2022] [Accepted: 02/22/2022] [Indexed: 11/20/2022]
Abstract
Novel cell-based assays were developed to assess antibody-dependence cellular cytotoxicity (ADCC) antibodies against both vaccine and a representative circulation strain HA and NA proteins for the 2014-15 influenza season. The four assays using target cells stably expressing one of the four proteins worked well. In pre- and post-vaccine sera from 70 participants in a pre-season vaccine trial, we found ADCC antibodies and a rise in ADCC antibody titer against target cells expressing the 4 proteins but a much higher titer for the vaccine than the circulating HA in both pre-and post-vaccine sera. These differences in HA ADCC antibodies were not reflected in differences in HA binding antibodies. Our observations suggested that relatively minor changes on the subtype HA can result in large differences in ADCC activity.
Collapse
Affiliation(s)
- Xuemin Chen
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Atlanta, GA, USA
| | - He-Ying Sun
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Atlanta, GA, USA
| | - Chun Yi Lee
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
| | - Christina A Rostad
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Jessica Trost
- Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, United States; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
| | - Rodrigo B Abreu
- Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Athens, GA, USA
| | - Michael A Carlock
- Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Athens, GA, USA
| | - Jason R Wilson
- Molecular Virology and Vaccine Team, Influenza and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Disease, OID, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Shane Gansebom
- Molecular Virology and Vaccine Team, Influenza and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Disease, OID, Centers for Disease Control and Prevention, Atlanta, GA, United States; (CDC/DDID/NCIRD/ID) GDIT, Federal Civilian Division, 2 Corporate Square; Ste 100, Atlanta, GA, 30329, USA
| | - Ted M Ross
- Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Athens, GA, USA; Department of Infectious Diseases, University of Georgia, Athens, GA, United States
| | - David A Steinhauer
- Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, United States
| | - Evan J Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States
| | - Larry J Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, United States; Emory-UGA Center of Excellence of Influenza Research and Surveillance (CEIRS), Atlanta, GA, USA.
| |
Collapse
|
14
|
Ha B, Jadhao S, Hussaini L, Gibson T, Stephens K, Salazar L, Ciric C, Taylor M, Rouphael N, Edupuganti S, Rostad CA, Tompkins SM, Anderson EJ, Anderson LJ. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. Microbiol Spectr 2021; 9:e0045821. [PMID: 34494855 PMCID: PMC8557898 DOI: 10.1128/spectrum.00458-21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 08/08/2021] [Indexed: 01/19/2023] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a global pandemic with over 152 million cases and 3.19 million deaths reported by early May 2021. Understanding the serological response to SARS-CoV-2 is critical to determining the burden of infection and disease (coronavirus disease 2019 [COVID-19]) and transmission dynamics. We developed a capture IgM assay because it should have better sensitivity and specificity than the commonly used indirect assay. Here, we report the development and performance of a capture IgM enzyme-linked immunosorbent assay (ELISA) and a companion indirect IgG ELISA for the spike (S) and nucleocapsid (N) proteins and the receptor-binding domain (RBD) of S. We found that among the IgM ELISAs, the S ELISA was positive in 76% of 55 serum samples from SARS-CoV-2 PCR-positive patients, the RBD ELISA was positive in 55% of samples, and the N ELISA was positive in 15% of samples. The companion indirect IgG ELISAs were positive for S in 89% of the 55 serum samples, RBD in 78%, and N in 85%. While the specificities for IgM RBD, S, and N ELISAs and IgG S and RBD ELISAs were 97% to 100%, the specificity of the N IgG ELISA was lower (89%). RBD-specific IgM antibodies became undetectable by 3 to 6 months, and S IgM reached low levels at 6 months. The corresponding IgG S, RBD, and N antibodies persisted with some decreases in levels over this time period. These capture IgM ELISAs and the companion indirect IgG ELISAs should enhance serologic studies of SARS-CoV-2 infections. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has inflicted tremendous loss of lives, overwhelmed health care systems, and disrupted all aspects of life worldwide since its emergence in Wuhan, China, in December 2019. Detecting current and past infection by PCR or serology is important to understanding and controlling SARS-CoV-2. With increasing prevalence of past infection or vaccination, IgG antibodies are less helpful in diagnosing a current infection. IgM antibodies indicate a more recent infection and can supplement PCR diagnosis. We report an alternative method, capture IgM, to detect serum IgM antibodies, which should be more sensitive and specific than most currently used methods. We describe this capture IgM assay and a companion indirect IgG assay for the SARS-CoV-2 spike (S), nucleocapsid (N), and receptor-binding domain (RBD) proteins. These assays can add value to diagnostic and serologic studies of coronavirus disease 2019 (COVID-19).
Collapse
Affiliation(s)
- Binh Ha
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| | - Samadhan Jadhao
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| | - Laila Hussaini
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| | - Theda Gibson
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| | - Kathy Stephens
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| | - Luis Salazar
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| | - Caroline Ciric
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| | - Meg Taylor
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| | - Nadine Rouphael
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Srilatha Edupuganti
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Christina A. Rostad
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| | - S. Mark Tompkins
- Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA
- Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA
- Emory-UGA Centers of Excellence for Influenza Research and Surveillance (CEIRS), Athens, Georgia, USA
| | - Evan J. Anderson
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Larry J. Anderson
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Health Care of Atlanta, Atlanta, Georgia, USA
| |
Collapse
|
15
|
Connelly AR, Jeong BM, Coden ME, Cao JY, Chirkova T, Rosas-Salazar C, Cephus JY, Anderson LJ, Newcomb DC, Hartert TV, Berdnikovs S. Metabolic Reprogramming of Nasal Airway Epithelial Cells Following Infant Respiratory Syncytial Virus Infection. Viruses 2021; 13:2055. [PMID: 34696488 PMCID: PMC8538412 DOI: 10.3390/v13102055] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Revised: 10/07/2021] [Accepted: 10/09/2021] [Indexed: 12/15/2022] Open
Abstract
Respiratory syncytial virus (RSV) is a seasonal mucosal pathogen that infects the ciliated respiratory epithelium and results in the most severe morbidity in the first six months of life. RSV is a common cause of acute respiratory infection during infancy and is an important early-life risk factor strongly associated with asthma development. While this association has been repeatedly demonstrated, limited progress has been made on the mechanistic understanding in humans of the contribution of infant RSV infection to airway epithelial dysfunction. An active infection of epithelial cells with RSV in vitro results in heightened central metabolism and overall hypermetabolic state; however, little is known about whether natural infection with RSV in vivo results in lasting metabolic reprogramming of the airway epithelium in infancy. To address this gap, we performed functional metabolomics, 13C glucose metabolic flux analysis, and RNA-seq gene expression analysis of nasal airway epithelial cells (NAECs) sampled from infants between 2-3 years of age, with RSV infection or not during the first year of life. We found that RSV infection in infancy was associated with lasting epithelial metabolic reprogramming, which was characterized by (1) significant increase in glucose uptake and differential utilization of glucose by epithelium; (2) altered preferences for metabolism of several carbon and energy sources; and (3) significant sexual dimorphism in metabolic parameters, with RSV-induced metabolic changes most pronounced in male epithelium. In summary, our study supports the proposed phenomenon of metabolic reprogramming of epithelial cells associated with RSV infection in infancy and opens exciting new venues for pursuing mechanisms of RSV-induced epithelial barrier dysfunction in early life.
Collapse
Affiliation(s)
- Andrew R. Connelly
- Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; (A.R.C.); (B.M.J.); (M.E.C.); (J.Y.C.)
| | - Brian M. Jeong
- Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; (A.R.C.); (B.M.J.); (M.E.C.); (J.Y.C.)
| | - Mackenzie E. Coden
- Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; (A.R.C.); (B.M.J.); (M.E.C.); (J.Y.C.)
| | - Jacob Y. Cao
- Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; (A.R.C.); (B.M.J.); (M.E.C.); (J.Y.C.)
| | - Tatiana Chirkova
- Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA; (T.C.); (L.J.A.)
| | - Christian Rosas-Salazar
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (C.R.-S.); (J.-Y.C.); (D.C.N.)
| | - Jacqueline-Yvonne Cephus
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (C.R.-S.); (J.-Y.C.); (D.C.N.)
| | - Larry J. Anderson
- Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA; (T.C.); (L.J.A.)
| | - Dawn C. Newcomb
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (C.R.-S.); (J.-Y.C.); (D.C.N.)
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37203, USA
| | - Tina V. Hartert
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37203, USA
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37203, USA
| | - Sergejs Berdnikovs
- Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; (A.R.C.); (B.M.J.); (M.E.C.); (J.Y.C.)
| |
Collapse
|
16
|
Lapp SA, Edara VV, Lu A, Lai L, Hussaini L, Chahroudi A, Anderson LJ, Suthar MS, Anderson EJ, Rostad CA. Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection. PLoS One 2021; 16:e0256482. [PMID: 34449792 PMCID: PMC8396729 DOI: 10.1371/journal.pone.0256482] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 08/06/2021] [Indexed: 11/19/2022] Open
Abstract
Background The effects of pre-existing endemic human coronavirus (HCoV) immunity on SARS-CoV-2 serologic and clinical responses are incompletely understood. Objectives We sought to determine the effects of prior exposure to HCoV Betacoronavirus HKU1 spike protein on serologic responses to SARS-CoV-2 spike protein after intramuscular administration in mice. We also sought to understand the baseline seroprevalence of HKU1 spike antibodies in healthy children and to measure their correlation with SARS-CoV-2 binding and neutralizing antibodies in children hospitalized with acute coronavirus disease 2019 (COVID-19) or multisystem inflammatory syndrome (MIS-C). Methods Groups of 5 mice were injected intramuscularly with two doses of alum-adjuvanted HKU1 spike followed by SARS-CoV-2 spike; or the reciprocal regimen of SARS-Cov-2 spike followed by HKU1 spike. Sera collected 21 days following each injection was analyzed for IgG antibodies to HKU1 spike, SARS-CoV-2 spike, and SARS-CoV-2 neutralization. Sera from children hospitalized with acute COVID-19, MIS-C or healthy controls (n = 14 per group) were analyzed for these same antibodies. Results Mice primed with SARS-CoV-2 spike and boosted with HKU1 spike developed high titers of SARS-CoV-2 binding and neutralizing antibodies; however, mice primed with HKU1 spike and boosted with SARS-CoV-2 spike were unable to mount neutralizing antibodies to SARS-CoV-2. HKU1 spike antibodies were detected in all children with acute COVID-19, MIS-C, and healthy controls. Although children with MIS-C had significantly higher HKU1 spike titers than healthy children (GMT 37239 vs. 7551, P = 0.012), these titers correlated positively with both SARS-CoV-2 binding (r = 0.7577, P<0.001) and neutralizing (r = 0.6201, P = 0.001) antibodies. Conclusions Prior murine exposure to HKU1 spike protein completely impeded the development of neutralizing antibodies to SARS-CoV-2, consistent with original antigenic sin. In contrast, the presence of HKU1 spike IgG antibodies in children with acute COVID-19 or MIS-C was not associated with diminished neutralizing antibody responses to SARS-CoV-2.
Collapse
Affiliation(s)
- Stacey A. Lapp
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
| | - Venkata Viswanadh Edara
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
- Yerkes Primate Center, Emory University, Atlanta, GA, United States of America
| | - Austin Lu
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
| | - Lilin Lai
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
- Yerkes Primate Center, Emory University, Atlanta, GA, United States of America
| | - Laila Hussaini
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
| | - Ann Chahroudi
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
| | - Larry J. Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
| | - Mehul S. Suthar
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
- Yerkes Primate Center, Emory University, Atlanta, GA, United States of America
| | - Evan J. Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
- Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States of America
| | - Christina A. Rostad
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States of America
- Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, United States of America
- * E-mail:
| |
Collapse
|
17
|
Salimi V, Viegas M, Trento A, Agoti CN, Anderson LJ, Avadhanula V, Bahl J, Bont L, Brister JR, Cane PA, Galiano M, Graham BS, Hatcher EL, Hellferscee O, Henke DM, Hirve S, Jackson S, Keyaerts E, Kragten-Tabatabaie L, Lindstrom S, Nauwelaers I, Nokes DJ, Openshaw PJ, Peret TC, Piedra PA, Ramaekers K, Rector A, Trovão NS, von Gottberg A, Zambon M, Zhang W, Williams TC, Barr IG, Buchholz UJ. Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerg Infect Dis 2021; 27:1-9. [PMID: 34013862 PMCID: PMC8153853 DOI: 10.3201/eid2706.204608] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Human respiratory syncytial virus (HRSV) is the leading viral cause of serious pediatric respiratory disease, and lifelong reinfections are common. Its 2 major subgroups, A and B, exhibit some antigenic variability, enabling HRSV to circulate annually. Globally, research has increased the number of HRSV genomic sequences available. To ensure accurate molecular epidemiology analyses, we propose a uniform nomenclature for HRSV-positive samples and isolates, and HRSV sequences, namely: HRSV/subgroup identifier/geographic identifier/unique sequence identifier/year of sampling. We also propose a template for submitting associated metadata. Universal nomenclature would help researchers retrieve and analyze sequence data to better understand the evolution of this virus.
Collapse
|
18
|
Jadhao SJ, Ha B, McCracken C, Gebretsadik T, Rosas-Salazar C, Chappell J, Das S, Hartert T, Anderson LJ. Performance evaluation of antibody tests for detecting infant respiratory syncytial virus infection. J Med Virol 2021; 93:3439-3445. [PMID: 33325064 PMCID: PMC8046717 DOI: 10.1002/jmv.26736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 10/20/2020] [Accepted: 12/12/2020] [Indexed: 11/12/2022]
Abstract
Respiratory syncytial virus (RSV) infection is a major cause of respiratory tract disease in young children and throughout life. Infant infection is also associated with later respiratory morbidity including asthma. With a prospective birth cohort study of RSV and asthma, we evaluated the performance of an RSV antibody enzyme-linked immunoassay (EIA) for detecting prior infant RSV infection. Infant RSV infection was determined by biweekly respiratory illness surveillance plus RSV polymerase chain reaction (PCR) testing in their first RSV season and serum RSV antibodies after the season at approximately 1 year of age. RSV antibodies were detected by RSV A and B lysate EIA. Antibody and PCR results on 1707 children included 327 RSV PCR positive (PCR+) and 1380 not RSV+. Of 327 PCR+ children, 314 (96%) were lysate EIA positive and 583 out of 1380 (42%) children not PCR+ were positive. We compared the lysate EIA to RSV F, group A G (Ga), and group B G (Gb) protein antibody EIAs in a subset of 226 sera, 118 PCR+ children (97 group A and 21 group B) and 108 not PCR+. In this subset, 117 out of 118 (99%) RSV PCR+ children were positive by both the F and lysate EIAs and 103 out of 118 (87%) were positive by the Ga and/or Gb EIAs. Comparison of the two G EIAs indicated the infecting group correctly in 100 out of 118 (86%) and incorrectly in 1 out of 118 (1%). The lysate and F EIAs are sensitive for detecting infant infection and the two G EIAs can indicate the group of an earlier primary infection.
Collapse
Affiliation(s)
- Samadhan J. Jadhao
- Department of Pediatrics, Emory University and Children’s Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Binh Ha
- Department of Pediatrics, Emory University and Children’s Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Courtney McCracken
- Department of Pediatrics, Emory University and Children’s Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Tebeb Gebretsadik
- Department of Medicine, Biostatistics and Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Christian Rosas-Salazar
- Department of Medicine, Biostatistics and Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - James Chappell
- Department of Medicine, Biostatistics and Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Suman Das
- Department of Medicine, Biostatistics and Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Tina Hartert
- Department of Medicine, Biostatistics and Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Larry J. Anderson
- Department of Pediatrics, Emory University and Children’s Healthcare of Atlanta, Atlanta, Georgia, USA
| |
Collapse
|
19
|
Cervantes-Barragan L, Vanderheiden A, Royer CJ, Davis-Gardner ME, Ralfs P, Chirkova T, Anderson LJ, Grakoui A, Suthar MS. Plasmacytoid dendritic cells produce type I interferon and reduce viral replication in airway epithelial cells after SARS-CoV-2 infection. bioRxiv 2021. [PMID: 34013278 DOI: 10.1101/2021.05.12.443948] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Infection with SARS-CoV-2 has caused a pandemic of unprecedented dimensions. SARS-CoV-2 infects airway and lung cells causing viral pneumonia. The importance of type I interferon (IFN) production for the control of SARS-CoV-2 infection is highlighted by the increased severity of COVID-19 in patients with inborn errors of type I IFN response or auto-antibodies against IFN-α. Plasmacytoid dendritic cells (pDCs) are a unique immune cell population specialized in recognizing and controlling viral infections through the production of high concentrations of type I IFN. In this study, we isolated pDCs from healthy donors and showed that pDCs are able to recognize SARS-CoV-2 and rapidly produce large amounts of type I IFN. Sensing of SARS-CoV-2 by pDCs was independent of viral replication since pDCs were also able to recognize UV-inactivated SARS-CoV-2 and produce type I IFN. Transcriptional profiling of SARS-CoV-2 and UV-SARS-CoV-2 stimulated pDCs also showed a rapid type I and III IFN response as well as induction of several chemokines, and the induction of apoptosis in pDCs. Moreover, we modeled SARS-CoV-2 infection in the lung using primary human airway epithelial cells (pHAEs) and showed that co-culture of pDCs with SARS-CoV-2 infected pHAEs induces an antiviral response and upregulation of antigen presentation in pHAE cells. Importantly, the presence of pDCs in the co-culture results in control of SARS-CoV-2 replication in pHAEs. Our study identifies pDCs as one of the key cells that can recognize SARS-CoV-2 infection, produce type I and III IFN and control viral replication in infected cells. Importance Type I interferons (IFNs) are a major part of the innate immune defense against viral infections. The importance of type I interferon (IFN) production for the control of SARS-CoV-2 infection is highlighted by the increased severity of COVID-19 in patients with defects in the type I IFN response. Interestingly, many cells are not able to produce type I IFN after being infected with SARS-CoV-2 and cannot control viral infection. In this study we show that plasmacytoid dendritic cells are able to recognize SARS-CoV-2 and produce type I IFN, and that pDCs are able to help control viral infection in SARS-CoV-2 infected airway epithelial cells.
Collapse
|
20
|
Chen X, Anderson LJ, Rostad CA, Ding L, Lai L, Mulligan M, Rouphael N, Natrajan MS, McCracken C, Anderson EJ. Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay. J Immunol Methods 2020; 488:112900. [PMID: 33075363 DOI: 10.1016/j.jim.2020.112900] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2020] [Revised: 10/09/2020] [Accepted: 10/12/2020] [Indexed: 11/19/2022]
Abstract
Zika virus (ZIKV) has become a global public health issue due to its teratogenicity and ability to cause Guillain-Barré syndrome in adults. Although anti-ZIKV envelope protein neutralizing antibodies correlate with protection, the non-neutralizing function of ZIKV antibodies including antibody-dependent cell-mediated cytotoxicity (ADCC) is incompletely understood. To study the role of ADCC antibodies during ZIKV infections, we generated a stably transfected, dual-reporter target cell line with inducible expression of a chimeric ZIKV prM-E protein on the cell surface as the target cell for the assay. By using this assay, nine of ten serum samples from ZIKV-infected patients had >20% ADCC killing of target cells, whereas none of the 12 healthy control sera had >10% ADCC killing. We also observed a time-dependent ADCC response in 2 patients with Zika. This demonstrates that this assay can detect ZIKV ADCC with high sensitivity and specificity, which could be useful for measurement of ADCC responses to ZIKV infection or vaccination.
Collapse
Affiliation(s)
- Xuemin Chen
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Larry J Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Christina A Rostad
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Lingmei Ding
- Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, Cincinnati, OH, USA
| | - Lilin Lai
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Division of Infectious Diseases and Microbiology and NYU Langone Vaccine Center, New York University, New York City, New York, USA
| | - Mark Mulligan
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Division of Infectious Diseases and Microbiology and NYU Langone Vaccine Center, New York University, New York City, New York, USA
| | - Nadine Rouphael
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Muktha S Natrajan
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Courtney McCracken
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
| | - Evan J Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
| |
Collapse
|
21
|
Ha B, Yang JE, Chen X, Jadhao SJ, Wright ER, Anderson LJ. Two RSV Platforms for G, F, or G+F Proteins VLPs. Viruses 2020; 12:v12090906. [PMID: 32824936 PMCID: PMC7551478 DOI: 10.3390/v12090906] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 08/13/2020] [Accepted: 08/17/2020] [Indexed: 12/24/2022] Open
Abstract
Respiratory syncytial virus (RSV) causes substantial lower respiratory tract disease in children and at-risk adults. Though there are no effective anti-viral drugs for acute disease or licensed vaccines for RSV, palivizumab prophylaxis is available for some high risk infants. To support anti-viral and vaccine development efforts, we developed an RSV virus-like particle (VLP) platform to explore the role RSV F and G protein interactions in disease pathogenesis. Since VLPs are immunogenic and a proven platform for licensed human vaccines, we also considered these VLPs as potential vaccine candidates. We developed two RSV VLP platforms, M+P and M+M2-1 that had F and G, F and a G peptide, or a truncated F and G on their surface. Immunoblots of sucrose gradient purified particles showed co-expression of M, G, and F with both VLP platforms. Electron microscopy imaging and immunogold labeling confirmed VLP-like structures with surface exposed projections consistent with F and G proteins. In mice, the VLPs induced both anti-F and -G protein antibodies and, on challenge, reduced lung viral titer and inflammation. These data show that these RSV VLP platforms provide a tool to study the structure of F and G and their interactions and flexible platforms to develop VLP vaccines in which all components contribute to RSV-specific immune responses.
Collapse
Affiliation(s)
- Binh Ha
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA; (B.H.); (X.C.); (S.J.J.)
| | - Jie E. Yang
- Department of Biochemistry, University of Wisconsin, Madison, WI 53706, USA;
| | - Xuemin Chen
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA; (B.H.); (X.C.); (S.J.J.)
| | - Samadhan J. Jadhao
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA; (B.H.); (X.C.); (S.J.J.)
| | - Elizabeth R. Wright
- Department of Biochemistry, University of Wisconsin, Madison, WI 53706, USA;
- Cryo-Electron Microscopy Research Center, Department of Biochemistry, University of Wisconsin, Madison, WI 53706, USA
- Morgridge Institute for Research, Madison, WI 53715, USA
- Correspondence: (E.R.W.); (L.J.A.); Tel.: +1-608-265-0666 (E.R.W.); +1-404-712-6604 (L.J.A.); Fax: +1-608-265-4693 (E.R.W.); +1-404-727-9223 (L.J.A.)
| | - Larry J. Anderson
- Division of Pediatric Infectious Diseases, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA; (B.H.); (X.C.); (S.J.J.)
- Correspondence: (E.R.W.); (L.J.A.); Tel.: +1-608-265-0666 (E.R.W.); +1-404-712-6604 (L.J.A.); Fax: +1-608-265-4693 (E.R.W.); +1-404-727-9223 (L.J.A.)
| |
Collapse
|
22
|
Chirkova T, Ha B, Rimawi BH, Oomens AGP, Hartert TV, Anderson LJ. In vitro model for the assessment of human immune responses to subunit RSV vaccines. PLoS One 2020; 15:e0229660. [PMID: 32191728 PMCID: PMC7081972 DOI: 10.1371/journal.pone.0229660] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Accepted: 02/12/2020] [Indexed: 01/22/2023] Open
Abstract
Respiratory syncytial virus (RSV) is the single most important cause of serious lower respiratory tract disease in infants and young children worldwide and a high priority for vaccine development. Despite over 50 years of research, however, no vaccine is yet available. One block to vaccine development is an incomplete understanding of the aberrant memory response to the formalin-inactivated RSV vaccine (FI-RSV) given to children in the 1960s. This vaccine caused enhanced respiratory disease (ERD) with later natural RSV infection. Concern that any non-live virus vaccine may also cause ERD has blocked development of subunit vaccines for young children. A number of animal FI-RSV studies suggest various immune mechanisms behind ERD. However, other than limited data from the original FI-RSV trial, there is no information on the human ERD-associated responses. An in vitro model with human blood specimens may shed light on the immune memory responses likely responsible for ERD. Memory T cell responses to an antigen are guided by the innate responses, particularly dendritic cells that present an antigen in conjunction with co-stimulatory molecules and cytokine signaling. Our in vitro model involves human monocyte derived dendritic cells (moDC) and allogenic T cell cultures to assess innate responses that direct T cell responses. Using this model, we evaluated human responses to live RSV, FI-RSV, and subunit RSV G vaccines (G-containing virus-like particles, G-VLP). Similar to findings in animal studies, FI-RSV induced prominent Th2/Th17-biased responses with deficient type-1 responses compared to live virus. Responses to G-VLPs were similar to live virus, i.e. biased towards a Th1 and not a Th2/Th17. Also mutating CX3C motif in G gave a more pronounced moDC responses associated with type-1 T cell responses. This in vitro model identifies human immune responses likely associated with ERD and provides another pre-clinical tool to assess the safety of RSV vaccines.
Collapse
Affiliation(s)
- Tatiana Chirkova
- Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Emory University, Atlanta, Georgia, United States of America
| | - Binh Ha
- Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Emory University, Atlanta, Georgia, United States of America
| | - Bassam H. Rimawi
- Maternal-Fetal Medicine, WakeMed Health & Hospitals, Raleigh, North Carolina, United States of America
| | - Antonius G. P. Oomens
- Department of Veterinary Pathobiology, Center for Veterinary Health Sciences Oklahoma State University, Stillwater, Oklahoma, United States of America
| | - Tina V. Hartert
- Department of Medicine, Division of Allergy, Pulmonary & Critical Care Medicine, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America
| | - Larry J. Anderson
- Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Emory University, Atlanta, Georgia, United States of America
- * E-mail:
| |
Collapse
|
23
|
Affiliation(s)
- Larry J Anderson
- Department of Pediatrics, Emory University Atlanta, Georgia.,Children's Healthcare of Atlanta, Georgia
| | - Teresa C Peret
- Respiratory Viruses Branch, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Pedro A Piedra
- Department of Molecular Virology and Microbiology and Department of Pediatrics, Baylor College of Medicine, Houston, Texas
| |
Collapse
|
24
|
Rajan D, O'Keefe EL, Travers C, McCracken C, Geoghegan S, Caballero MT, Acosta PL, Polack F, Anderson LJ. MUC5AC Levels Associated With Respiratory Syncytial Virus Disease Severity. Clin Infect Dis 2019; 67:1441-1444. [PMID: 29878077 DOI: 10.1093/cid/ciy340] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 05/28/2018] [Indexed: 02/05/2023] Open
Abstract
To assess MUC5AC as a biomarker for respiratory syncytial virus (RSV) disease severity, we tested nasal aspirates from RSV+ children with mild, moderate, and severe disease. Levels were significantly higher in those in the severe and moderate groups compared to mild group, indicating MUC5AC may be a useful biomarker for RSV disease severity.
Collapse
Affiliation(s)
- Devi Rajan
- Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Georgia
| | - Evan L O'Keefe
- Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Georgia
| | - Curtis Travers
- Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Georgia
| | - Courtney McCracken
- Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Georgia
| | | | | | - Patricio L Acosta
- Consejo Nacional de Investigaciones Cientificas y Tecnicas, Buenos Aires, Argentina
| | | | - Larry J Anderson
- Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Georgia
| |
Collapse
|
25
|
Moccia E, Papatheodorou E, Miles CJ, Merghani A, Malhotra A, Zaidi A, Sanna GD, Homfray T, Bunce N, Anderson LJ, Tome-Esteban MT, Behr E, Sharma S, Finocchiaro G, Papadakis M. P3683Diagnosis of arrhythmogenic cardiomyopathy and overlap with cardiac adaptation to exercise: insights from a cardiac magnetic resonance study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) is often challenging and some structural abnormalities typical of the disease may overlap with changes reflective of cardiac adaptation to exercise.
Purpose
The aim of the study was to assess the performance of the cardiac magnetic resonance (CMR) 2010 Task Force Criteria (TFC) in a cohort of patients with definite diagnosis of ARVC and define the overlap with a cohort of highly trained athletes of similar age and sex.
Methods
We compared the CMR features of 43 patients (mean age 49±17 years, 49% males, 32 (74%) genotyped) with a definite diagnosis of ARVC according to the revised TFC to 97 (mean age 45±16 years, 61% males) highly-trained athletes of similar age and sex, in whom cardiac disease was excluded after comprehensive work-up.
Results
The CMR was abnormal in 37 (86%) patients. The right ventricle (RV) was affected in isolation in 17 (39%) patients, with 18 (42%) patients exhibiting biventricular involvement and 2 (5%) patients showing isolated left ventricular (LV) involvement. The most common RV abnormalities were regional wall motion abnormalities (RWMA) (n=34; 79%), RV dilatation fulfilling a major or minor volume TFC (n=18; 42%), impaired systolic function (RV ejection fraction (EF) ≤45%: n=17; 40%) and myocardial fibrosis (n=13; 30%). The predominant LV abnormality was myocardial fibrosis (n=20; 47%), with a small proportion of patients exhibiting RWMA (n=6; 14%) and impaired systolic function (LVEF <50%: n=6; 14%). Twenty-three (53%) patients fulfilled a major (n=14; 32%) or a minor (n=9; 21%) CMR TFC. Sixteen (16%) athletes exceeded the cut-off values for RV volumes used as a major (n=10; 10%) or a minor (n=6; 6%) TFC with an inverse relationship between age and RV volumes (r=−41, p=0.001). None of the athletes fulfilled the TFC for RV ejection fraction. Applying the CMR TFC to the ARVC patient population showed a sensitivity of 33% for the major and 28% for the minor criteria. Applying the RV volume and systolic function TFC values in the entire study population showed a sensitivity of 53%, a specificity between 83% and an accuracy of 0.68.
Conclusions
The great majority (86%) of patients with ARVC demonstrates structural abnormalities suggestive of cardiomyopathy on CMR but only 53% fulfills any of the CMR TFC. Only a small proportion (16%) of older athletes demonstrate significant RV dilatation that overlaps with the volume criteria for ARVC, in juxtaposition to younger athletes who exhibit a greater degree of overlap. The emergence of ARVC as a biventricular disease provides an opportunity to re-evaluate the diagnostic criteria and include LV involvement in conjunction with RV involvement to improve diagnostic accuracy.
Acknowledgement/Funding
CRY (Cardiac Risk in the Young) charity
Collapse
Affiliation(s)
- E Moccia
- University of Sassari, Clinical and Interventional Cardiology, Sassari, Italy
| | - E Papatheodorou
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - C J Miles
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - A Merghani
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - A Malhotra
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - A Zaidi
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - G D Sanna
- University of Sassari, Clinical and Interventional Cardiology, Sassari, Italy
| | - T Homfray
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - N Bunce
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - L J Anderson
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - M T Tome-Esteban
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - E Behr
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - S Sharma
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - G Finocchiaro
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| | - M Papadakis
- St George's University of London, Cardiology Clinical and Academic Group, London, United Kingdom
| |
Collapse
|
26
|
Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development. Front Immunol 2019; 10:1675. [PMID: 31402910 PMCID: PMC6677153 DOI: 10.3389/fimmu.2019.01675] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Accepted: 07/04/2019] [Indexed: 12/21/2022] Open
Abstract
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease in young children and a substantial contributor to respiratory tract disease throughout life and as such a high priority for vaccine development. However, after nearly 60 years of research no vaccine is yet available. The challenges to developing an RSV vaccine include the young age, 2-4 months of age, for the peak of disease, the enhanced RSV disease associated with the first RSV vaccine, formalin-inactivated RSV with an alum adjuvant (FI-RSV), and difficulty achieving protection as illustrated by repeat infections with disease that occur throughout life. Understanding the biology of infection and disease pathogenesis has and will continue to guide vaccine development. In this paper, we review the roles that RSV proteins play in the biology of infection and disease pathogenesis and the corresponding contribution to live attenuated and subunit RSV vaccines. Each of RSV's 11 proteins are in the design of one or more vaccines. The G protein's contribution to disease pathogenesis through altering host immune responses as well as its role in the biology of infection suggest it can make a unique contribution to an RSV vaccine, both live attenuated and subunit vaccines. One of G's potential unique contributions to a vaccine is the potential for anti-G immunity to have an anti-inflammatory effect independent of virus replication. Though an anti-viral effect is essential to an effective RSV vaccine, it is important to remember that the goal of a vaccine is to prevent disease. Thus, other effects of the infection, such as G's alteration of the host immune response may provide opportunities to induce responses that block this effect and improve an RSV vaccine. Keeping in mind the goal of a vaccine is to prevent disease and not virus replication may help identify new strategies for other vaccine challenges, such as improving influenza vaccines and developing HIV vaccines.
Collapse
Affiliation(s)
| | - Tatiana Chirkova
- Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, United States
| | - Larry J Anderson
- Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, United States
| |
Collapse
|
27
|
Ha B, Chirkova T, Boukhvalova MS, Sun HY, Walsh EE, Anderson CS, Mariani TJ, Anderson LJ. Mutation of Respiratory Syncytial Virus G Protein's CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells. Vaccines (Basel) 2019; 7:E69. [PMID: 31330970 PMCID: PMC6789749 DOI: 10.3390/vaccines7030069] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 07/14/2019] [Accepted: 07/16/2019] [Indexed: 01/18/2023] Open
Abstract
Despite being a high priority for vaccine development, no vaccine is yet available for respiratory syncytial virus (RSV). A live virus vaccine is the primary type of vaccine being developed for young children. In this report, we describe our studies of infected cotton rats and primary human airway epithelial cells (pHAECs) using an RSV r19F with a mutation in the CX3C chemokine motif in the RSV G protein (CX4C). Through this CX3C motif, RSV binds to the corresponding chemokine receptor, CX3CR1, and this binding contributes to RSV infection of pHAECs and virus induced host responses that contribute to disease. In both the cotton rat and pHAECs, the CX4C mutation decreased virus replication and disease and/or host responses to infection. Thus, this mutation, or other mutations that block binding to CX3CR1, has the potential to improve a live attenuated RSV vaccine by attenuating both infection and disease pathogenesis.
Collapse
Affiliation(s)
- Binh Ha
- Pediatric Infectious Diseases, Emory University and Children's Healthcare of Atlanta, Atlanta, GA 30322, USA
| | - Tatiana Chirkova
- Pediatric Infectious Diseases, Emory University and Children's Healthcare of Atlanta, Atlanta, GA 30322, USA
| | | | - He Ying Sun
- Pediatric Infectious Diseases, Emory University and Children's Healthcare of Atlanta, Atlanta, GA 30322, USA
| | - Edward E Walsh
- Department of Medicine, University of Rochester School of Medicine and Department of Medicine, Rochester General Hospital, Rochester, NY 14621, USA
| | - Christopher S Anderson
- Department of Neonatology, Program in Pediatric Molecular and Personalized Medicine, and Department of Microbiology and Immunology, University of Rochester School of Medicine, Rochester, NY 14642, USA
| | - Thomas J Mariani
- Department of Neonatology, Program in Pediatric Molecular and Personalized Medicine, and Department of Microbiology and Immunology, University of Rochester School of Medicine, Rochester, NY 14642, USA
| | - Larry J Anderson
- Pediatric Infectious Diseases, Emory University and Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
| |
Collapse
|
28
|
Chinnadurai R, Rajan D, Qayed M, Arafat D, Garcia M, Liu Y, Kugathasan S, Anderson LJ, Gibson G, Galipeau J. Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. Cell Rep 2019; 22:2504-2517. [PMID: 29490284 DOI: 10.1016/j.celrep.2018.02.013] [Citation(s) in RCA: 118] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 09/11/2017] [Accepted: 02/02/2018] [Indexed: 02/07/2023] Open
Abstract
Assays that can characterize MSC immune potency need to be identified for use in advanced clinical trials. MSCs possess a number of putative regenerative and immunomodulatory properties, and an assay matrix approach may best capture involved effector pathways. We have tested two assay systems to measure the potency of MSCs derived from human subjects: MSC secretome analysis and a quantitative RNA-based array for genes specific to immunomodulatory and homing properties of MSCs. Secretome analysis identified a unique cytokine signature that is upregulated by MSCs or downregulated in responder PBMCs and correlated with T cell suppression. Use of interferon-γ as a surrogate for the action of activated PBMCs on MSCs served as an alternative for the use of human PBMCs as responder cells in a potency assay. Our approach and results define and simplify the multifunctional or matrix responses of MSCs and may serve as a platform for robust potency analysis.
Collapse
Affiliation(s)
- Raghavan Chinnadurai
- Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin - Madison, Madison, WI 53705, USA
| | - Devi Rajan
- Department of Pediatrics, Children's Healthcare of Atlanta, Emory University, Atlanta, GA 30322, USA
| | - Muna Qayed
- Department of Pediatrics, Children's Healthcare of Atlanta, Emory University, Atlanta, GA 30322, USA
| | - Dalia Arafat
- School of Biology, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | | | - Yifei Liu
- Department of Statistics, University of Wisconsin - Madison, Madison, WI 53706, USA
| | - Subra Kugathasan
- Department of Pediatrics, Children's Healthcare of Atlanta, Emory University, Atlanta, GA 30322, USA
| | - Larry J Anderson
- Department of Pediatrics, Children's Healthcare of Atlanta, Emory University, Atlanta, GA 30322, USA
| | - Greg Gibson
- School of Biology, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | - Jacques Galipeau
- Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin - Madison, Madison, WI 53705, USA.
| |
Collapse
|
29
|
Schuchat A, Anderson LJ, Rodewald LE, Cox NJ, Hajjeh R, Pallansch MA, Messonnier NE, Jernigan DB, Wharton M. Progress in Vaccine-Preventable and Respiratory Infectious Diseases-First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006-2015. Emerg Infect Dis 2019; 24:1178-1187. [PMID: 29916350 PMCID: PMC6038744 DOI: 10.3201/eid2407.171699] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The need for closer linkages between scientific and programmatic areas focused on addressing vaccine-preventable and acute respiratory infections led to establishment of the National Center for Immunization and Respiratory Diseases (NCIRD) at the Centers for Disease Control and Prevention. During its first 10 years (2006–2015), NCIRD worked with partners to improve preparedness and response to pandemic influenza and other emergent respiratory infections, provide an evidence base for addition of 7 newly recommended vaccines, and modernize vaccine distribution. Clinical tools were developed for improved conversations with parents, which helped sustain childhood immunization as a social norm. Coverage increased for vaccines to protect adolescents against pertussis, meningococcal meningitis, and human papillomavirus–associated cancers. NCIRD programs supported outbreak response for new respiratory pathogens and oversaw response of the Centers for Disease Control and Prevention to the 2009 influenza A(H1N1) pandemic. Other national public health institutes might also find closer linkages between epidemiology, laboratory, and immunization programs useful.
Collapse
|
30
|
Turi KN, Shankar J, Anderson LJ, Rajan D, Gaston K, Gebretsadik T, Das SR, Stone C, Larkin EK, Rosas-Salazar C, Brunwasser SM, Moore ML, Peebles RS, Hartert TV. Infant Viral Respiratory Infection Nasal Immune-Response Patterns and Their Association with Subsequent Childhood Recurrent Wheeze. Am J Respir Crit Care Med 2018; 198:1064-1073. [PMID: 29733679 PMCID: PMC6221572 DOI: 10.1164/rccm.201711-2348oc] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Accepted: 05/07/2018] [Indexed: 02/06/2023] Open
Abstract
RATIONALE Recurrent wheeze and asthma are thought to result from alterations in early life immune development following respiratory syncytial virus (RSV) infection. However, prior studies of the nasal immune response to infection have assessed only individual cytokines, which does not capture the whole spectrum of response to infection. OBJECTIVES To identify nasal immune phenotypes in response to RSV infection and their association with recurrent wheeze. METHODS A birth cohort of term healthy infants born June to December were recruited and followed to capture the first infant RSV infection. Nasal wash samples were collected during acute respiratory infection, viruses were identified by RT-PCR, and immune-response analytes were assayed using a multianalyte bead-based panel. Immune-response clusters were identified using machine learning, and association with recurrent wheeze at age 1 and 2 years was assessed using logistic regression. MEASUREMENTS AND MAIN RESULTS We identified two novel and distinct immune-response clusters to RSV and human rhinovirus. In RSV-infected infants, a nasal immune-response cluster characterized by lower non-IFN antiviral immune-response mediators, and higher type-2 and type-17 cytokines was significantly associated with first and second year recurrent wheeze. In comparison, we did not observe this in infants with human rhinovirus acute respiratory infection. Based on network analysis, type-2 and type-17 cytokines were central to the immune response to RSV, whereas growth factors and chemokines were central to the immune response to human rhinovirus. CONCLUSIONS Distinct immune-response clusters during infant RSV infection and their association with risk of recurrent wheeze provide insights into the risk factors for and mechanisms of asthma development.
Collapse
Affiliation(s)
- Kedir N. Turi
- Division of Allergy, Pulmonary, and Critical Care Medicine and
| | - Jyoti Shankar
- Infectious Disease Group, J. Craig Venter Institute, Rockville, Maryland; and
| | | | - Devi Rajan
- Department of Pediatrics, Emory University, Atlanta, Georgia
| | - Kelsey Gaston
- Department of Pediatrics, Emory University, Atlanta, Georgia
| | | | - Suman R. Das
- Division of Infectious Diseases, Department of Medicine
- Infectious Disease Group, J. Craig Venter Institute, Rockville, Maryland; and
| | - Cosby Stone
- Division of Allergy, Pulmonary, and Critical Care Medicine and
| | - Emma K. Larkin
- Division of Allergy, Pulmonary, and Critical Care Medicine and
| | | | | | - Martin L. Moore
- Department of Pediatrics, Emory University, Atlanta, Georgia
| | | | - Tina V. Hartert
- Division of Allergy, Pulmonary, and Critical Care Medicine and
| |
Collapse
|
31
|
Turi KN, Romick-Rosendale L, Gebretsadik T, Watanabe M, Brunwasser S, Anderson LJ, Moore ML, Larkin EK, Peebles RS, Hartert TV. Using urine metabolomics to understand the pathogenesis of infant respiratory syncytial virus (RSV) infection and its role in childhood wheezing. Metabolomics 2018; 14:135. [PMID: 30830453 PMCID: PMC6557166 DOI: 10.1007/s11306-018-1431-z] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Accepted: 09/21/2018] [Indexed: 12/31/2022]
Abstract
BACKGROUND Respiratory syncytial virus (RSV) infection in infants causes significant morbidity and is the strongest risk factor associated with asthma. Metabolites, which reflect the interactions between host cell and virus, provide an opportunity to identify the pathways that underlie severe infections and asthma development. OBJECTIVE To study metabolic profile differences between infants with RSV infection, and human rhinovirus (HRV) infection, and healthy infants. To compare infant metabolic differences between children who do and do not wheeze. METHODS In a term birth cohort, urine was collected while healthy and during acute viral respiratory infection with RSV and HRV. We used 1H-NMR to identify urinary metabolites. Multivariate and univariate statistics were used to discriminate metabolic profiles of infants with either RSV ARI, or HRV ARI, and healthy infants. Multivariable logistic regression was used to assess the association of urine metabolites with 1st-, 2nd-, and 3rd-year recurrent wheezing. RESULTS Several metabolites in nicotinate and nicotinamide metabolism pathways were down-regulated in infants with RSV infection compared to healthy controls. There were no significant differences in metabolite profiles between infants with RSV infection and infants with HRV Infection. Alanine was strongly associated with reduced risk of 1st-year wheezing (OR 0.18[0.0, 0.46]) and 2nd-year wheezing (OR 0.31[0.13, 0.73]), while 2-hydroxyisobutyric acid was associated with increased 3rd-year wheezing (OR 5.02[1.49, 16.93]) only among the RSV infected subset. CONCLUSION The metabolites associated with infant RSV infection and recurrent-wheezing are indicative of viral takeover of the cellular machinery and resources to enhance virulence, replication, and subversion of the host immune-response, highlighting metabolic pathways important in the pathogenesis of RSV infection and wheeze development.
Collapse
Affiliation(s)
- Kedir N Turi
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, 2525 West End Avenue, Suite 450, Nashville, TN, 37203, USA
| | - Lindsey Romick-Rosendale
- Department of Pathology, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Tebeb Gebretsadik
- Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Miki Watanabe
- Department of Pathology, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Steven Brunwasser
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, 2525 West End Avenue, Suite 450, Nashville, TN, 37203, USA
| | | | - Martin L Moore
- Department of Pediatrics, Emory University, Atlanta, GA, USA
| | - Emma K Larkin
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, 2525 West End Avenue, Suite 450, Nashville, TN, 37203, USA
| | - Ray Stokes Peebles
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, 2525 West End Avenue, Suite 450, Nashville, TN, 37203, USA
| | - Tina V Hartert
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, 2525 West End Avenue, Suite 450, Nashville, TN, 37203, USA.
| |
Collapse
|
32
|
Caidi H, Miao C, Thornburg NJ, Tripp RA, Anderson LJ, Haynes LM. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. Antiviral Res 2018; 154:149-157. [PMID: 29678551 DOI: 10.1016/j.antiviral.2018.04.014] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Revised: 04/12/2018] [Accepted: 04/16/2018] [Indexed: 01/04/2023]
Abstract
RSV continues to be a high priority for vaccine and antiviral drug development. Unfortunately, no safe and effective RSV vaccine is available and treatment options are limited. Over the past decade, several studies have focused on the role of RSV G protein on viral entry, viral neutralization, and RSV-mediated pathology. Anti-G murine monoclonal antibody (mAb) 131-2G treatment has been previously shown to reduce weight loss, bronchoalveolar lavage (BAL) cell number, airway reactivity, and Th2-type cytokine production in RSV-infected mice more rapidly than a commercial humanized monoclonal antibody (mAb) against RSV F protein (Palivizumab). In this study, we have tested two human anti-RSV G mAbs, 2B11 and 3D3, by both prophylactic and therapeutic treatment for RSV in the BALB/c mouse model. Both anti-G mAbs reduced viral load, leukocyte infiltration and IFN-γ and IL-4 expression in cell-free BAL supernatants emphasizing the potential of anti-G mAbs as anti-inflammatory and antiviral strategies.
Collapse
Affiliation(s)
- Hayat Caidi
- National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA
| | - Congrong Miao
- National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA
| | - Natalie J Thornburg
- National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
| | - Ralph A Tripp
- College of Veterinary Medicine, Department of Infectious Diseases, University of Georgia, Athens, GA, USA
| | - Larry J Anderson
- Division of Pediatric Infectious Diseases, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Lia M Haynes
- National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA
| |
Collapse
|
33
|
Kim L, Rha B, Abramson JS, Anderson LJ, Byington CL, Chen GL, DeVincenzo J, Edwards KM, Englund JA, Falsey AR, Griffin MR, Karron RA, Martin KG, Meissner HC, Munoz FM, Pavia AT, Piedra PA, Schaffner W, Simões EAF, Singleton R, Talbot HK, Walsh EE, Zucker JR, Gerber SI. Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines. Clin Infect Dis 2018; 65:1020-1025. [PMID: 28903503 DOI: 10.1093/cid/cix432] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 05/03/2017] [Indexed: 11/14/2022] Open
Abstract
Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently. No effective antivirals or vaccines for RSV are approved for use in the United States; however, there are at least 50 vaccines and monoclonal antibody products in development, with those targeting older adults and pregnant women (to protect young infants) in phase 2 and 3 clinical trials. Unanswered questions regarding RSV epidemiology need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of impact and future recommendations. The Centers for Disease Control and Prevention (CDC) convened a technical consultation to gather input from external subject matter experts on their individual perspectives regarding evidence gaps in current RSV epidemiology in the United States, potential studies and surveillance platforms needed to fill these gaps, and prioritizing efforts. Participants articulated their individual views, and CDC staff synthesized individuals' input into this report.
Collapse
Affiliation(s)
- Lindsay Kim
- Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Brian Rha
- Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Jon S Abramson
- Wake Forest School of Medicine, Winston-Salem, North Carolina
| | | | | | - Grace L Chen
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
| | - John DeVincenzo
- Pediatrics.,Microbiology, Immunology, and Biochemistry, University of Tennessee Center for Health Sciences.,Children's Foundation Research Institute, Lebonheur Children's Hospital, Memphis
| | - Kathryn M Edwards
- Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
| | | | - Ann R Falsey
- Department of Medicine, University of Rochester School of Medicine, New York
| | - Marie R Griffin
- Health Policy.,Medicine, Vanderbilt University Medical Center.,Mid-South Geriatric Research Education and Clinical Center, VA Tennessee Valley Health Care System, Nashville
| | - Ruth A Karron
- Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
| | - Karen G Martin
- Council of State and Territorial Epidemiologists, Atlanta, Georgia.,Minnesota Department of Health, St Paul
| | - H Cody Meissner
- Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts
| | - Flor M Munoz
- Departments of Pediatrics, Molecular Virology, and Microbiology, Baylor College of Medicine, Houston, Texas
| | - Andrew T Pavia
- Departments of Pediatrics and Medicine, University of Utah School of Medicine, Salt Lake City
| | - Pedro A Piedra
- Departments of Pediatrics, Molecular Virology, and Microbiology, Baylor College of Medicine, Houston, Texas
| | - William Schaffner
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Eric A F Simões
- Department of Pediatrics, University of Colorado School of Medicine.,Department of Epidemiology, Center for Global Health, Colorado School of Public Health, Aurora
| | - Rosalyn Singleton
- Alaska Native Tribal Health Consortium.,Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage
| | - H Keipp Talbot
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Edward E Walsh
- Department of Medicine, University of Rochester School of Medicine, New York
| | - Jane R Zucker
- New York City Department of Health and Mental Hygiene, Bureau of Immunization.,Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Susan I Gerber
- Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| |
Collapse
|
34
|
Rosas-Salazar C, Shilts MH, Tovchigrechko A, Schobel S, Chappell JD, Larkin EK, Gebretsadik T, Halpin RA, Nelson KE, Moore ML, Anderson LJ, Peebles RS, Das SR, Hartert TV. Nasopharyngeal Lactobacillus is associated with a reduced risk of childhood wheezing illnesses following acute respiratory syncytial virus infection in infancy. J Allergy Clin Immunol 2018; 142:1447-1456.e9. [PMID: 29330010 DOI: 10.1016/j.jaci.2017.10.049] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 09/27/2017] [Accepted: 10/11/2017] [Indexed: 02/06/2023]
Abstract
BACKGROUND Early life acute respiratory infection (ARI) with respiratory syncytial virus (RSV) has been strongly associated with the development of childhood wheezing illnesses, but the pathways underlying this association are poorly understood. OBJECTIVE To examine the role of the nasopharyngeal microbiome in the development of childhood wheezing illnesses following RSV ARI in infancy. METHODS We conducted a nested cohort study of 118 previously healthy, term infants with confirmed RSV ARI by RT-PCR. We used next-generation sequencing of the V4 region of the 16S ribosomal RNA gene to characterize the nasopharyngeal microbiome during RSV ARI. Our main outcome of interest was 2-year subsequent wheeze. RESULTS Of the 118 infants, 113 (95.8%) had 2-year outcome data. Of these, 46 (40.7%) had parental report of subsequent wheeze. There was no association between the overall taxonomic composition, diversity, and richness of the nasopharyngeal microbiome during RSV ARI with the development of subsequent wheeze. However, the nasopharyngeal detection and abundance of Lactobacillus was consistently higher in infants who did not develop this outcome. Lactobacillus also ranked first among the different genera in a model distinguishing infants with and without subsequent wheeze. CONCLUSIONS The nasopharyngeal detection and increased abundance of Lactobacillus during RSV ARI in infancy are associated with a reduced risk of childhood wheezing illnesses at age 2 years.
Collapse
Affiliation(s)
- Christian Rosas-Salazar
- Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tenn; Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tenn
| | - Meghan H Shilts
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn; Infectious Disease Group, J. Craig Venter Institute, Rockville, Md; Infectious Disease Group, J. Craig Venter Institute, La Jolla, Calif
| | | | - Seth Schobel
- Bioinformatics Group, J. Craig Venter Institute, Rockville, Md
| | - James D Chappell
- Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tenn
| | - Emma K Larkin
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tenn; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn
| | - Tebeb Gebretsadik
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tenn; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tenn
| | - Rebecca A Halpin
- Infectious Disease Group, J. Craig Venter Institute, Rockville, Md
| | - Karen E Nelson
- Genomic Medicine Group, J. Craig Venter Institute, La Jolla, Calif
| | - Martin L Moore
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tenn; Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga
| | - Larry J Anderson
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tenn; Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga
| | - R Stokes Peebles
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tenn; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn
| | - Suman R Das
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn; Infectious Disease Group, J. Craig Venter Institute, Rockville, Md; Infectious Disease Group, J. Craig Venter Institute, La Jolla, Calif.
| | - Tina V Hartert
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tenn; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.
| |
Collapse
|
35
|
Rosas-Salazar C, Shilts MH, Tovchigrechko A, Chappell JD, Larkin EK, Nelson KE, Moore ML, Anderson LJ, Das SR, Hartert TV. Nasopharyngeal Microbiome in Respiratory Syncytial Virus Resembles Profile Associated with Increased Childhood Asthma Risk. Am J Respir Crit Care Med 2017; 193:1180-3. [PMID: 27174483 DOI: 10.1164/rccm.201512-2350le] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
| | | | | | | | - Emma K Larkin
- 1 Vanderbilt University School of Medicine Nashville, Tennessee
| | | | - Martin L Moore
- 3 Emory University School of Medicine Atlanta, Georgia and.,4 Children's Healthcare of Atlanta Atlanta, Georgia
| | - Larry J Anderson
- 3 Emory University School of Medicine Atlanta, Georgia and.,4 Children's Healthcare of Atlanta Atlanta, Georgia
| | - Suman R Das
- 2 J. Craig Venter Institute Rockville, Maryland
| | - Tina V Hartert
- 1 Vanderbilt University School of Medicine Nashville, Tennessee
| |
Collapse
|
36
|
Rajan D, Chinnadurai R, O'Keefe EL, Boyoglu-Barnum S, Todd SO, Hartert TV, Galipeau J, Anderson LJ. Protective role of Indoleamine 2,3 dioxygenase in Respiratory Syncytial Virus associated immune response in airway epithelial cells. Virology 2017; 512:144-150. [PMID: 28963880 DOI: 10.1016/j.virol.2017.09.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 08/31/2017] [Accepted: 09/07/2017] [Indexed: 11/30/2022]
Abstract
RSV is a major cause of severe lower respiratory infection in infants and young children. With no vaccine yet available, it is important to clarify mechanisms of disease pathogenesis. Since indoleamine-2,3-dioxygenase (IDO) is an immunomodulatory enzyme and is upregulated with RSV infection, we studied it in vivo during infection of BALB/c mice and in vitro in A549 cells. RSV infection upregulated IDO transcripts in vivo and in vitro. IDO siRNA decreased IDO transcripts ~2 fold compared to control siRNA after RSV infection but this decrease did not affect RSV replication. In the presence of IFN-γ, siRNA-induced a decrease in IDO expression that was associated with an increase in virus replication and increased levels of IL-6, IL-8, CXCL10 and CCL4. Thus, our results show IDO is upregulated with RSV infection and this upregulation likely participates with IFN-γ in inhibition of virus replication and suppression of some host cell responses to infection.
Collapse
Affiliation(s)
- Devi Rajan
- Department of Pediatrics, Emory Children's Center, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia
| | - Raghavan Chinnadurai
- Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA
| | - Evan L O'Keefe
- Department of Pediatrics, Emory Children's Center, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia
| | | | - Sean O Todd
- Department of Pediatrics, Emory Children's Center, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia
| | - Tina V Hartert
- Department of Medicine, Vanderbilt Institute for Medicine & Public Health, Nashville, TN, USA
| | - Jacques Galipeau
- Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA
| | - Larry J Anderson
- Department of Pediatrics, Emory Children's Center, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia.
| |
Collapse
|
37
|
Achten NB, Wu P, Bont L, Blanken MO, Gebretsadik T, Chappell JD, Wang L, Yu C, Larkin EK, Carroll KN, Anderson LJ, Moore ML, Sloan CD, Hartert TV. Interference Between Respiratory Syncytial Virus and Human Rhinovirus Infection in Infancy. J Infect Dis 2017; 215:1102-1106. [PMID: 28368456 DOI: 10.1093/infdis/jix031] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Accepted: 03/15/2017] [Indexed: 11/14/2022] Open
Abstract
Background Respiratory syncytial virus (RSV) and human rhinovirus (HRV) are the most common viruses associated with acute respiratory tract infections in infancy. Viral interference is important in understanding respiratory viral circulation and the impact of vaccines. Methods To study viral interference, we evaluated cases of RSV and HRV codetection by polymerase chain reaction in 2 prospective birth cohort studies (the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure [INSPIRE] study and the Tennessee Children's Respiratory Initiative [TCRI]) and a double-blinded, randomized, controlled trial (MAKI), using adjusted multivariable regression analyses. Results Among 3263 respiratory tract samples, 24.5% (798) and 37.3% (1216) were RSV and HRV positive, respectively. The odds of HRV infection were significantly lower in RSV-infected infants in all cohorts, with adjusted odds ratios of 0.30 (95% confidence interval [CI], .22-.40 in the INSPIRE study, 0.18 (95% CI, .11-.28) in the TCRI (adjusted for disease severity), and 0.34 (95% CI, .16-.72) in the MAKI trial. HRV infection was significantly more common among infants administered RSV immunoprophylaxis, compared with infants who did not receive immunoprophylaxis (OR, 1.65; 95% CI, 1.65-2.39). Conclusions A negative association of RSV on HRV codetection was consistently observed across populations, seasons, disease severity, and geographical regions. Suppressing RSV infection by RSV immunoprophylaxis might increase the risk of having HRV infection.
Collapse
Affiliation(s)
- Niek B Achten
- Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, the Netherlands
| | - Pingsheng Wu
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine
| | - Louis Bont
- Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, the Netherlands
| | - Maarten O Blanken
- Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, the Netherlands
| | | | | | | | | | - Emma K Larkin
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine
| | - Kecia N Carroll
- Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Larry J Anderson
- Department of Pediatrics, Emory University, Atlanta, Georgia; and
| | - Martin L Moore
- Department of Pediatrics, Emory University, Atlanta, Georgia; and
| | - Chantel D Sloan
- Department of Health Science, College of Life Sciences, Brigham Young University, Provo, Utah
| | - Tina V Hartert
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine
| |
Collapse
|
38
|
Rosas-Salazar C, Shilts MH, Tovchigrechko A, Schobel S, Chappell JD, Larkin EK, Shankar J, Yooseph S, Nelson KE, Halpin RA, Moore ML, Anderson LJ, Peebles RS, Das SR, Hartert TV. Differences in the Nasopharyngeal Microbiome During Acute Respiratory Tract Infection With Human Rhinovirus and Respiratory Syncytial Virus in Infancy. J Infect Dis 2017; 214:1924-1928. [PMID: 27923952 DOI: 10.1093/infdis/jiw456] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Accepted: 09/21/2016] [Indexed: 12/28/2022] Open
Abstract
Respiratory viruses alter the nasopharyngeal microbiome and may be associated with a distinct microbial signature. To test this hypothesis, we compared the nasopharyngeal microbiome of 135 previously healthy infants with acute respiratory infection due to human rhinovirus (HRV; n = 52) or respiratory syncytial virus (RSV; n = 83). The nasopharyngeal microbiome was assessed by sequencing the V4 region of the 16S ribosomal RNA. Respiratory viruses were identified by quantitative reverse-transcription polymerase chain reaction. We found significant differences in the overall taxonomic composition and abundance of certain bacterial genera between infants infected with HRV and those infected with RSV. Our results suggest that respiratory tract viral infections are associated with different nasopharyngeal microbial profiles.
Collapse
Affiliation(s)
| | - Meghan H Shilts
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.,Infectious Disease Group.,Infectious Disease Group
| | | | - Seth Schobel
- Bioinformatics Group, J. Craig Venter Institute, Rockville, Maryland
| | | | - Emma K Larkin
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Jyoti Shankar
- Bioinformatics Group, J. Craig Venter Institute, Rockville, Maryland
| | | | - Karen E Nelson
- Genomic Medicine Group, J. Craig Venter Institute, La Jolla, California
| | | | - Martin L Moore
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia
| | - Larry J Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia
| | - R Stokes Peebles
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Suman R Das
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.,Infectious Disease Group.,Infectious Disease Group
| | - Tina V Hartert
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| |
Collapse
|
39
|
Roberts JN, Graham BS, Karron RA, Munoz FM, Falsey AR, Anderson LJ, Marshall V, Kim S, Beeler JA. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. Vaccine 2016; 34:4843-4849. [PMID: 27566900 DOI: 10.1016/j.vaccine.2016.07.057] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Accepted: 07/29/2016] [Indexed: 10/21/2022]
Abstract
Respiratory syncytial virus (RSV) is the most common cause of serious acute lower respiratory illness in infants and young children and a significant cause of disease burden in the elderly and immunocompromised. There are no licensed RSV vaccines to address this significant public health need. While advances in vaccine technologies have led to a recent resurgence in RSV vaccine development, the immune correlates of protection against RSV and the immunology of vaccine-associated enhanced respiratory disease (ERD) remain poorly understood. FDA's Center for Biologics Evaluation and Research (CBER) and NIH's National Institute of Allergy and Infectious Diseases (NIAID) organized and co-sponsored an RSV Vaccines Workshop in Bethesda, Maryland on June 1 and 2, 2015. The goal of the conference was to convene scientists, regulators, and industry stakeholders to discuss approaches to RSV vaccine development within the context of three target populations - infants and children, pregnant women, and individuals >60years of age. The agenda included topics related to RSV vaccine development in general, as well as considerations specific to each target population, such as clinical and serological endpoints. The meeting focused on vaccine development for high income countries (HIC), because issues relevant to vaccine development for low and middle income countries (LMIC) have been discussed in other forums. This manuscript summarizes the discussion of clinical, scientific, and regulatory perspectives, research gaps, and lessons learned.
Collapse
Affiliation(s)
- Jeffrey N Roberts
- Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
| | - Barney S Graham
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Ruth A Karron
- Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Flor M Munoz
- Department of Pediatrics and Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA
| | - Ann R Falsey
- Division of Infectious Diseases, Department of Medicine, Rochester General Hospital, University of Rochester, Rochester, NY, USA
| | - Larry J Anderson
- Department of Pediatrics, School of Medicine, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - V Marshall
- Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA
| | - Sonnie Kim
- Division of Microbiology and Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Judy A Beeler
- Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA
| |
Collapse
|
40
|
Ku DN, Ku SK, Helfman B, McCarty NA, Wolff BJ, Winchell JM, Anderson LJ. Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis. F1000Res 2016; 5:1920. [PMID: 27781088 PMCID: PMC5054809 DOI: 10.12688/f1000research.9251.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/27/2016] [Indexed: 12/02/2022] Open
Abstract
Background: Identifying lung pathogens and acute spikes in lung counts remain a challenge in the treatment of patients with cystic fibrosis (CF). Bacteria from the deep lung may be sampled from aerosols produced during coughing. Methods: A new device was used to collect and measure bacteria levels from cough aerosols of patients with CF. Sputum and oral specimens were also collected and measured for comparison. Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, and Streptococcus mitis were detected in specimens using Real-Time Polymerase Chain Reaction (RT-PCR) molecular assays. Results: Twenty adult patients with CF and 10 healthy controls participated. CF related bacteria (CFRB) were detected in 13/20 (65%) cough specimens versus 15/15 (100%) sputum specimens. Commensal S. mitis was present in 0/17 (0%, p=0.0002) cough specimens and 13/14 (93%) sputum samples. In normal controls, no bacteria were collected in cough specimens but 4/10 (40%) oral specimens were positive for CFRB. Conclusions: Non-invasive cough aerosol collection may detect lower respiratory pathogens in CF patients, with similar specificity and sensitivity to rates detected by BAL, without contamination by oral CFRB or commensal bacteria.
Collapse
Affiliation(s)
- David N. Ku
- Georgia Institute of Technology, Atlanta, GA, 30332, USA
- MD Innovate, Inc, Decatur, GA, 30030, USA
| | | | - Beth Helfman
- Emory Children’s Center for Cystic Fibrosis Research, Emory University, Atlanta, GA, 30322, USA
- Department of Pediatrics, Emory University, Atlanta, 30322, USA
| | - Nael A. McCarty
- Emory Children’s Center for Cystic Fibrosis Research, Emory University, Atlanta, GA, 30322, USA
- Department of Pediatrics, Emory University, Atlanta, 30322, USA
| | - Bernard J. Wolff
- Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA
| | - Jonas M. Winchell
- Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA
| | - Larry J. Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University and Children’s Healthcare of Atlanta, Atlanta, GA, 30322, USA
| |
Collapse
|
41
|
Sloan CD, Gebretsadik T, Rosas-Salazar C, Wu P, Carroll KN, Mitchel E, Anderson LJ, Larkin EK, Hartert TV. Seasonal Timing of Infant Bronchiolitis, Apnea and Sudden Unexplained Infant Death. PLoS One 2016; 11:e0158521. [PMID: 27404386 PMCID: PMC4942135 DOI: 10.1371/journal.pone.0158521] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Accepted: 06/16/2016] [Indexed: 11/23/2022] Open
Abstract
Rates of Sudden Unexplained Infant Death (SUID), bronchiolitis, and central apnea increase in winter in temperate climates. Though associations between these three conditions are suggested, more work is required to establish if there is a causal pathway linking bronchiolitis to SUID through inducing central apnea. Utilizing a large population-based cohort of infants studied over a 20-year period (n = 834,595, from birth years 1989–2009)), we analyzed ecological associations between timing of SUID cases, bronchiolitis, and apnea healthcare visits. Data were analyzed between 2013 and 2015. We used a Cox Proportional Hazards model to analyze possible interactions between maternal smoking and maternal asthma with infant bronchiolitis on time to SUID. SUID and bronchiolitis both occurred more frequently in winter. An increase in bronchiolitis clinical visits occurred within a few days prior to apnea visits. We found a temporal relationship between infant bronchiolitis and apnea. In contrast, no peak in SUID cases was seen during peaks of bronchiolitis. Among those without any bronchiolitis visits, maternal smoking was associated with an increased risk of SUID: Hazard Ratio (HR) of 2.38 (95% CI: 2.11, 2.67, p-value <0.001). Maternal asthma was associated with an increased risk of SUID among infants with at least one bronchiolitis visit: HR of 2.40 (95% CI: 1.04, 5.54, p-value = 0.04). Consistent trends between bronchiolitis, apnea, and SUID were not established due to small numbers of SUID cases. However, interaction analysis revealed potential differential associations of bronchiolitis and SUID by maternal smoking, maternal asthma status.
Collapse
Affiliation(s)
- Chantel D. Sloan
- Department of Health Science, Brigham Young University, Provo, Utah, United States of America
| | - Tebeb Gebretsadik
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
- Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
| | - Christian Rosas-Salazar
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
- Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
| | - Pingsheng Wu
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
- Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
| | - Kecia N. Carroll
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
- Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
| | - Edward Mitchel
- Department of Health Policy,Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
| | - Larry J. Anderson
- Department of Pediatrics, Pediatric Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America
| | - Emma K. Larkin
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
| | - Tina V. Hartert
- Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
- Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
- * E-mail:
| |
Collapse
|
42
|
Shilts MH, Rosas-Salazar C, Tovchigrechko A, Larkin EK, Torralba M, Akopov A, Halpin R, Peebles RS, Moore ML, Anderson LJ, Nelson KE, Hartert TV, Das SR. Minimally Invasive Sampling Method Identifies Differences in Taxonomic Richness of Nasal Microbiomes in Young Infants Associated with Mode of Delivery. Microb Ecol 2016; 71:233-42. [PMID: 26370110 PMCID: PMC4688197 DOI: 10.1007/s00248-015-0663-y] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/22/2015] [Accepted: 08/17/2015] [Indexed: 05/26/2023]
Abstract
To date, there is a limited understanding of the role of the airway microbiome in the early life development of respiratory diseases such as asthma, partly due to a lack of simple and minimally invasive sample collection methods. In order to characterize the baseline microbiome of the upper respiratory tract (URT) in infants, a comparatively non-invasive method for sampling the URT microbiome suitable for use in infants was developed. Microbiome samples were collected by placing filter paper in the nostrils of 33 healthy, term infants enrolled as part of the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure (INSPIRE) study. After bacterial genomic DNA was extracted from the filters, amplicons were generated with universal primers targeting the V1-V3 region of the 16S rRNA gene. This method was capable of capturing a wide variety of taxa expected to inhabit the nasal cavity. Analyses stratifying subjects by demographic and environmental factors previously observed or predicted to influence microbial communities were performed. Microbial community richness was found to be higher in infants who had been delivered via Cesarean section and in those who had been formula-fed; an association was observed between diet and delivery, which confounds this analysis. We have established a baseline URT microbiome using a non-invasive filter paper nasal sampling for this population, and future studies will be performed in this large observational cohort of infants to investigate the relationship between viral infections, the URT microbiota, and the development of childhood wheezing illnesses.
Collapse
Affiliation(s)
- Meghan H Shilts
- Infectious Diseases Group, J. Craig Venter Institute, 9704 Medical Center Dr., Rockville, MD, 20850, USA
| | | | | | - Emma K Larkin
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Manolito Torralba
- Genomic Medicine Group, J. Craig Venter Institute, Rockville, MD, USA
| | - Asmik Akopov
- Infectious Diseases Group, J. Craig Venter Institute, 9704 Medical Center Dr., Rockville, MD, 20850, USA
| | - Rebecca Halpin
- Infectious Diseases Group, J. Craig Venter Institute, 9704 Medical Center Dr., Rockville, MD, 20850, USA
| | - R Stokes Peebles
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Martin L Moore
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
| | - Larry J Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
| | - Karen E Nelson
- Genomic Medicine Group, J. Craig Venter Institute, Rockville, MD, USA
| | - Tina V Hartert
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Suman R Das
- Infectious Diseases Group, J. Craig Venter Institute, 9704 Medical Center Dr., Rockville, MD, 20850, USA.
| |
Collapse
|
43
|
Ostadabbas S, Sebkhi N, Zhang M, Rahim S, Anderson LJ, Lee FEH, Ghovanloo M. A Vision-Based Respiration Monitoring System for Passive Airway Resistance Estimation. IEEE Trans Biomed Eng 2015; 63:1904-1913. [PMID: 26660514 DOI: 10.1109/tbme.2015.2505732] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Airway resistance is the mechanical cause of most of the symptoms in obstructive pulmonary disease, and can be considered as the primary measure of disease severity. A low-cost and noninvasive method to measure the airway resistance that does not require patient effort could be of great benefit in evaluating the severity of lung diseases, especially in patient population that are unable to use spirometry, such as young children. METHODS The Vision-Based Passive Airway Resistance Estimation (VB-PARE) technology is a passive method to measure airway resistance noninvasively. The airway resistance is estimated from: 1) airflow extracted from processing depth data captured by a Microsoft Kinect, and 2) Pulsus Paradoxus extracted from a pulse oximeter (SpO 2). RESULTS To verify the validity and accuracy of the VB-PARE, two phases of experiment were conducted. In Phase I, spontaneous breathing data was collected from 14 healthy participants with externally induced airway obstruction, and the accuracy of 76.2±13.8% was achieved in predicting three levels of obstruction severity. In Phase II, VB-PARE outputs were compared with the clinical results from 14 patients. VB-PARE estimated the tidal volume with an average error of 0.07±0.06 liter. Also, patients with airway obstruction were detected with 80% accuracy. CONCLUSION Using the information extracted from Kinect and SpO 2 , here, we present a quantitative method to measure the severity of airway obstruction without requiring active patient involvement. SIGNIFICANCE The proposed VB-PARE system contributes to the state-of-art respiration monitoring methods by expanding the idea of passive and noninvasive airway resistance measurement.
Collapse
|
44
|
Boyoglu-Barnum S, Todd SO, Chirkova T, Barnum TR, Gaston KA, Haynes LM, Tripp RA, Moore ML, Anderson LJ. An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology 2015; 483:117-25. [PMID: 25965801 PMCID: PMC4516680 DOI: 10.1016/j.virol.2015.02.035] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Revised: 01/04/2015] [Accepted: 02/18/2015] [Indexed: 12/13/2022]
Abstract
Respiratory syncytial virus (RSV) belongs to the family Paramyxoviridae and is the single most important cause of serious lower respiratory tract infections in young children, yet no highly effective treatment or vaccine is available. To clarify the potential for an anti-G mAb, 131-2G which has both anti-viral and anti-inflammatory effects, to effectively treat RSV disease, we determined the kinetics of its effect compared to the effect of the anti-F mAb, 143-6C on disease in mice. Treatment administered three days after RSV rA2-line19F (r19F) infection showed 131-2G decreased breathing effort, pulmonary mucin levels, weight loss, and pulmonary inflammation earlier and more effectively than treatment with mAb 143-6C. Both mAbs stopped lung virus replication at day 5 post-infection. These data show that, in mice, anti-G protein mAb is superior to treating disease during RSV infection than an anti-F protein mAb similar to Palivizumab. This combination of anti-viral and anti-inflammatory activity makes 131-2G a promising candidate for treating for active human RSV infection.
Collapse
Affiliation(s)
- Seyhan Boyoglu-Barnum
- Emory University Department of Pediatrics and Children׳s Healthcare of Atlanta, Atlanta, GA 30322, USA
| | - Sean O Todd
- Emory University Department of Pediatrics and Children׳s Healthcare of Atlanta, Atlanta, GA 30322, USA
| | - Tatiana Chirkova
- Emory University Department of Pediatrics and Children׳s Healthcare of Atlanta, Atlanta, GA 30322, USA
| | - Thomas R Barnum
- University of Georgia, Odum School of Ecology, Athens, GA 30602, USA
| | - Kelsey A Gaston
- Emory University Department of Pediatrics and Children׳s Healthcare of Atlanta, Atlanta, GA 30322, USA
| | - Lia M Haynes
- Division of Viral Diseases, NCIRD, CDC, Atlanta, GA 30333, USA
| | - Ralph A Tripp
- University of Georgia Department of Infectious Diseases, Animal Health Research Center, Athens, GA 30602, USA
| | - Martin L Moore
- Emory University Department of Pediatrics and Children׳s Healthcare of Atlanta, Atlanta, GA 30322, USA
| | - Larry J Anderson
- Emory University Department of Pediatrics and Children׳s Healthcare of Atlanta, Atlanta, GA 30322, USA.
| |
Collapse
|
45
|
Rosas-Salazar C, Gebretsadik T, Carroll KN, Reiss S, Wickersham N, Larkin EK, James KM, Miller EK, Anderson LJ, Hartert TV. Urine Club Cell 16-kDa Secretory Protein and Childhood Wheezing Illnesses After Lower Respiratory Tract Infections in Infancy. Pediatr Allergy Immunol Pulmonol 2015; 28:158-164. [PMID: 26421213 DOI: 10.1089/ped.2015.0528] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Background: Infants with lower respiratory tract infections (LRTIs) are at an increased risk of developing childhood wheezing illnesses (including asthma), but it is not currently possible to predict those at risk for these long-term outcomes. The current objective was to examine whether urine levels of club cell 16-kDa secretory protein (CC16) at the time of an infant LRTI are associated with the development of childhood wheezing illnesses. Methods: Prospective study of 133 previously healthy infants enrolled during a healthcare visit for a LRTI and followed longitudinally for childhood wheezing illnesses. Urine levels of CC16 at the time of enrollment were measured after validating a commercially available enzyme-linked immunosorbent assay kit for serum. The outcome of interest was parental report of subsequent childhood wheeze (defined as ≥1 episode of wheezing following the initial LRTI) at the 1-year follow-up visit. Logistic regression was used for the main analysis. Results: The median (interquartile range) urine levels of CC16 (ng/mg of creatinine) at the time of an infant LRTI were 11.1 (7.7-20.1) for infants with subsequent childhood wheeze and 13.4 (8.3-61.1) for those without (p = 0.11). In the main multivariate analysis using a logarithmic transformation of the urine levels of CC16, a twofold increase in urine levels of CC16 was associated with ∼30% decreased odds (OR = 0.74 [95% confidence interval (CI) 0.56-0.98], p = 0.04) of subsequent childhood wheeze after adjustment for potential confounders. Conclusions: An inverse association was found between urine levels of CC16 at the time of an infant LRTI and the odds of subsequent childhood wheeze. Urine CC16 may be a useful biomarker of the development of childhood wheezing illnesses after LRTIs in infancy.
Collapse
Affiliation(s)
- Christian Rosas-Salazar
- Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee
| | - Tebeb Gebretsadik
- Department of Biostatistics, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee
| | - Kecia N Carroll
- Division of General Pediatrics, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee
| | - Sara Reiss
- Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee
| | - Nancy Wickersham
- Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee
| | - Emma K Larkin
- Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee
| | - Kristina M James
- Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee
| | - E Kathryn Miller
- Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee
| | - Larry J Anderson
- Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta , Atlanta, Georgia
| | - Tina V Hartert
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee
| |
Collapse
|
46
|
Chirkova T, Lin S, Oomens AGP, Gaston KA, Boyoglu-Barnum S, Meng J, Stobart CC, Cotton CU, Hartert TV, Moore ML, Ziady AG, Anderson LJ. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol 2015; 96:2543-2556. [PMID: 26297201 DOI: 10.1099/vir.0.000218] [Citation(s) in RCA: 99] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Respiratory syncytial virus (RSV) is a major cause of severe pneumonia and bronchiolitis in infants and young children, and causes disease throughout life. Understanding the biology of infection, including virus binding to the cell surface, should help develop antiviral drugs or vaccines. The RSV F and G glycoproteins bind cell surface heparin sulfate proteoglycans (HSPGs) through heparin-binding domains. The G protein also has a CX3C chemokine motif which binds to the fractalkine receptor CX3CR1. G protein binding to CX3CR1 is not important for infection of immortalized cell lines, but reportedly is so for primary human airway epithelial cells (HAECs), the primary site for human infection. We studied the role of CX3CR1 in RSV infection with CX3CR1-transfected cell lines and HAECs with variable percentages of CX3CR1-expressing cells, and the effect of anti-CX3CR1 antibodies or a mutation in the RSV CX3C motif. Immortalized cells lacking HSPGs had low RSV binding and infection, which was increased markedly by CX3CR1 transfection. CX3CR1 was expressed primarily on ciliated cells, and ∼50 % of RSV-infected cells in HAECs were CX3CR1+. HAECs with more CX3CR1-expressing cells had a proportional increase in RSV infection. Blocking G binding to CX3CR1 with anti-CX3CR1 antibody or a mutation in the CX3C motif significantly decreased RSV infection in HAECs. The kinetics of cytokine production suggested that the RSV/CX3CR1 interaction induced RANTES (regulated on activation normal T-cell expressed and secreted protein), IL-8 and fractalkine production, whilst it downregulated IL-15, IL1-RA and monocyte chemotactic protein-1. Thus, the RSV G protein/CX3CR1 interaction is likely important in infection and infection-induced responses of the airway epithelium, the primary site of human infection.
Collapse
Affiliation(s)
- Tatiana Chirkova
- Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Songbai Lin
- Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Antonius G P Oomens
- Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, Oklahoma, USA
| | - Kelsey A Gaston
- Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Seyhan Boyoglu-Barnum
- Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Jia Meng
- Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Christopher C Stobart
- Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Calvin U Cotton
- Division of Pediatric Pulmonology, Case Western University, Cleveland, Ohio, USA
| | - Tina V Hartert
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine and Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University, Nashville, Tennessee, USA
| | - Martin L Moore
- Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Assem G Ziady
- Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Larry J Anderson
- Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| |
Collapse
|
47
|
Larkin EK, Gebretsadik T, Moore ML, Anderson LJ, Dupont WD, Chappell JD, Minton PA, Peebles RS, Moore PE, Valet RS, Arnold DH, Rosas-Salazar C, Das SR, Polack FP, Hartert TV. Objectives, design and enrollment results from the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE). BMC Pulm Med 2015; 15:45. [PMID: 26021723 PMCID: PMC4506623 DOI: 10.1186/s12890-015-0040-0] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2015] [Accepted: 04/16/2015] [Indexed: 12/25/2022] Open
Abstract
Background Respiratory syncytial virus (RSV) lower respiratory tract infection (LRI) during infancy has been consistently associated with an increased risk of childhood asthma. In addition, evidence supports that this relationship is causal. However, the mechanisms through which RSV contributes to asthma development are not understood. The INSPIRE (Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure) study objectives are to: 1) characterize the host phenotypic response to RSV infection in infancy and the risk of recurrent wheeze and asthma, 2) identify the immune response and lung injury patterns of RSV infection that are associated with the development of early childhood wheezing illness and asthma, and 3) determine the contribution of specific RSV strains to early childhood wheezing and asthma development. This article describes the INSPIRE study, including study aims, design, recruitment results, and enrolled population characteristics. Methods/design The cohort is a population based longitudinal birth cohort of term healthy infants enrolled during the first months of life over a two year period. Respiratory infection surveillance was conducted from November to March of the first year of life, through surveys administered every two weeks. In-person illness visits were conducted if infants met pre-specified criteria for a respiratory illness visit. Infants will be followed annually to ages 3-4 years for assessment of the primary endpoint: wheezing illness. Nasal, urine, stool and blood samples were collected at various time points throughout the study for measurements of host and viral factors that predict wheezing illness. Nested case-control studies will additionally be used to address other primary and secondary hypotheses. Discussion In the INSPIRE study, 1952 infants (48% female) were enrolled during the two enrollment years and follow-up will continue through 2016. The mean age of enrollment was 60 days. During winter viral season, more than 14,000 surveillance surveys were carried out resulting in 2,103 respiratory illness visits on 1189 infants. First year follow-up has been completed on over 95% percent of participants from the first year of enrollment. With ongoing follow-up for wheezing and childhood asthma outcomes, the INSPIRE study will advance our understanding of the complex causal relationship between RSV infection and early childhood wheezing and asthma.
Collapse
Affiliation(s)
- Emma K Larkin
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
| | - Tebeb Gebretsadik
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
| | - Martin L Moore
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
| | - Larry J Anderson
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
| | - William D Dupont
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
| | - James D Chappell
- Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA.
| | - Patricia A Minton
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
| | - R Stokes Peebles
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
| | - Paul E Moore
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
| | - Robert S Valet
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
| | - Donald H Arnold
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
| | | | - Suman R Das
- Virology Department, J. Craig Venter Institute, Rockville, MD, USA.
| | - Fernando P Polack
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
| | - Tina V Hartert
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
| | | |
Collapse
|
48
|
Anderson LJ, Jarrett WF. Bovine leukosis in Great Britain. Bibl Haematol 2015; 30:193. [PMID: 5695482 DOI: 10.1159/000391250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
49
|
Choi BCK, Wigle DT, Johansen H, Losos J, Fair ME, Napke E, Anderson LJ, Davies JW, White K, Miller AB, Li FCK, Stachenko S, Lindsay J, Gaudette LA, Nair C, Levy I, Morrison H, Silins J, Bouchard F, Tonmyr L, Villeneuve PJ, McRae L, Johnson KC, Lane RS, Probert A. Status Report--Retracing the history of the early development of national chronic disease surveillance in Canada and the major role of the Laboratory Centre for Disease Control (LCDC) from 1972 to 2000. Health Promot Chronic Dis Prev Can 2015; 35:35-44. [PMID: 25915119 PMCID: PMC4910431 DOI: 10.24095/hpcdp.35.2.02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Health surveillance is the ongoing, systematic
use of routinely collected health
data to guide public health action in a
timely fashion.
This paper describes the creation and
growth of national surveillance systems
in Canada and their impact on chronic
disease and injury prevention.
In 2008, the authors started a review process
to retrace the history of the early development
of national chronic disease surveillance
in Canada from 1960 to 2000. A 1967
publication describes the history of the
development of the Laboratory of Hygiene
from 1921 to 1967. This review is a sequel
to that paper and describes the history of the
development of national chronic disease
surveillance in Canada before and after the
formation of the Laboratory Centre for
Disease Control (LCDC).
Collapse
Affiliation(s)
- B C K Choi
- Public Health Agency of Canada, Ottawa, Ontario, Canada
- Health Canada, Ottawa, Ontario, Canada
| | - D T Wigle
- Health Canada, Ottawa, Ontario, Canada
| | - H Johansen
- Health Canada, Ottawa, Ontario, Canada
- Statistics Canada, Ottawa, Ontario, Canada
| | - J Losos
- Health Canada, Ottawa, Ontario, Canada
- University of Ottawa, Ottawa, Ontario, Canada
| | - M E Fair
- Statistics Canada, Ottawa, Ontario, Canada
| | - E Napke
- Health Canada, Ottawa, Ontario, Canada
| | - L J Anderson
- Health Canada, Ottawa, Ontario, Canada
- Health and Social Policy Editing Consultant, Ottawa, Ontario, Canada
| | - J W Davies
- Health Canada, Ottawa, Ontario, Canada
- University of Ottawa, Ottawa, Ontario, Canada
| | - K White
- Health Canada, Ottawa, Ontario, Canada
- Statistics Canada, Ottawa, Ontario, Canada
| | - A B Miller
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - F C K Li
- Health Canada, Ottawa, Ontario, Canada
- Embassy of Canada, Beijing, China
| | - S Stachenko
- Public Health Agency of Canada, Ottawa, Ontario, Canada
- School of Public Health, University of Alberta, Edmonton, Alberta, Canada
| | - J Lindsay
- Health Canada, Ottawa, Ontario, Canada
- University of Ottawa, Ottawa, Ontario, Canada
| | - L A Gaudette
- Public Health Agency of Canada, Ottawa, Ontario, Canada
- Statistics Canada, Ottawa, Ontario, Canada
| | - C Nair
- Statistics Canada, Ottawa, Ontario, Canada
- Health Information Solutions, Ottawa, Ontario, Canada
| | - I Levy
- Health Canada, Ottawa, Ontario, Canada
- Ottawa Public Health, Ottawa, Ontario, Canada
| | - H Morrison
- Public Health Agency of Canada, Ottawa, Ontario, Canada
- Health Canada, Ottawa, Ontario, Canada
| | - J Silins
- Health Canada, Ottawa, Ontario, Canada
- Statistics Canada, Ottawa, Ontario, Canada
| | - F Bouchard
- Health Canada, Ottawa, Ontario, Canada
- Nunavik Regional Board of Health and Social Services, Kuujjuaq, Quebec, Canada
| | - L Tonmyr
- Public Health Agency of Canada, Ottawa, Ontario, Canada
- Health Canada, Ottawa, Ontario, Canada
| | - P J Villeneuve
- Health Canada, Ottawa, Ontario, Canada
- Carleton University, Ottawa, Ontario, Canada
| | - L McRae
- Public Health Agency of Canada, Ottawa, Ontario, Canada
- Health Canada, Ottawa, Ontario, Canada
| | - K C Johnson
- Public Health Agency of Canada, Ottawa, Ontario, Canada
- Health Canada, Ottawa, Ontario, Canada
| | - R S Lane
- Health Canada, Ottawa, Ontario, Canada
- Canadian Nuclear Safety Commission, Ottawa, Ontario, Canada
| | - A Probert
- Health Canada, Ottawa, Ontario, Canada
| |
Collapse
|
50
|
Rajan D, McCracken CE, Kopleman HB, Kyu SY, Lee FEH, Lu X, Anderson LJ. Human rhinovirus induced cytokine/chemokine responses in human airway epithelial and immune cells. PLoS One 2014; 9:e114322. [PMID: 25500821 PMCID: PMC4264758 DOI: 10.1371/journal.pone.0114322] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 11/06/2014] [Indexed: 11/23/2022] Open
Abstract
Infections with human rhinovirus (HRV) are commonly associated with acute upper and lower respiratory tract disease and asthma exacerbations. The role that HRVs play in these diseases suggests it is important to understand host-specific or virus-specific factors that contribute to pathogenesis. Since species A HRVs are often associated with more serious HRV disease than species B HRVs, differences in immune responses they induce should inform disease pathogenesis. To identify species differences in induced responses, we evaluated 3 species A viruses, HRV 25, 31 and 36 and 3 species B viruses, HRV 4, 35 and 48 by exposing human PBMCs to HRV infected Calu-3 cells. To evaluate the potential effect of memory induced by previous HRV infection on study responses, we tested cord blood mononuclear cells that should be HRV naïve. There were HRV-associated increases (significant increase compared to mock-infected cells) for one or more HRVs for IP-10 and IL-15 that was unaffected by addition of PBMCs, for MIP-1α, MIP-1β, IFN-α, and HGF only with addition of PBMCs, and for ENA-78 only without addition of PBMCs. All three species B HRVs induced higher levels, compared to A HRVs, of MIP-1α and MIP-1β with PBMCs and ENA-78 without PBMCs. In contrast, addition of CBMCs had less effect and did not induce MIP-1α, MIP-1β, or IFN-α nor block ENA-78 production. Addition of CBMCs did, however, increase IP-10 levels for HRV 35 and HRV 36 infection. The presence of an effect with PBMCs and no effect with CBMCs for some responses suggest differences between the two types of cells possibly because of the presence of HRV memory responses in PBMCs and not CBMCs or limited response capacity for the immature CBMCs relative to PBMCs. Thus, our results indicate that different HRV strains can induce different patterns of cytokines and chemokines; some of these differences may be due to differences in memory responses induced by past HRV infections, and other differences related to virus factors that can inform disease pathogenesis.
Collapse
Affiliation(s)
- Devi Rajan
- Department of Pediatrics, Emory Children's Center, Atlanta, Georgia, United States of America
| | - Courtney E. McCracken
- Department of Pediatrics, Emory Children's Center, Atlanta, Georgia, United States of America
| | - Hannah B. Kopleman
- Department of Pediatrics, Emory Children's Center, Atlanta, Georgia, United States of America
| | - Shuya Y. Kyu
- Division of Pulmonary, Allergy, & Critical Care Medicine, Emory University, Atlanta, Georgia, United States of America
| | - F. Eun-Hyung Lee
- Division of Pulmonary, Allergy, & Critical Care Medicine, Emory University, Atlanta, Georgia, United States of America
| | - Xiaoyan Lu
- Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - Larry J. Anderson
- Department of Pediatrics, Emory Children's Center, Atlanta, Georgia, United States of America
- * E-mail:
| |
Collapse
|